A mathematical model of tissue factor-induced blood coagulation: discrete sites of initiation and regulation under conditions of flow by Jordan, Sumanas W.
A MATHEMATICAL MODEL OF TISSUE FACTOR-INDUCED BLOOD 
COAGULATION: DISCRETE SITES OF INITIATION AND REGULATION UNDER 

























In Partial Fulfillment 
of the Requirements for the Degree 








Georgia Institute of Technology 
 
May 2010  
 
 
A MATHEMATICAL MODEL OF TISSUE FACTOR-INDUCED BLOOD 
COAGULATION: DISCRETE SITES OF INITIATION AND REGULATION UNDER 

























Dr. Elliot L. Chaikof, Advisor 
Departments of Surgery and Biomedical 
Engineering 
Emory University 
Georgia Institute of Technology 
 
Dr. Larry V. McIntire 
Department of Biomedical Engineering 
Emory University 
Georgia Institute of Technology 
 
Dr. Eberhard O. Voit 
Department of Biomedical Engineering 
Emory University 
Georgia Institute of Technology 
Dr. Stephen R. Hanson 
Department of Biomedical Engineering 
Oregon Health & Science University 
 
Dr. William J. Federspiel 
Department of Bioengineering 
University of Pittsburgh 
 
 
Date Approved: March 31, 2010
 iii 
ACKNOWLEDGEMENTS 
I owe my deepest gratitude to my thesis advisor, Dr. Elliot Chaikof, who provided 
not only scientific support and advice, but also personal mentorship.  Over the years, he 
has guided me through the struggles of defining and solving worthwhile problems as the 
work of my thesis grew despite myself.  By rare example and exceptional character, he 
has nurtured me from a second-year medical student to a burgeoning surgeon-scientist.  
It is an honor to acknowledge him as my mentor.   
I am grateful to the members of my thesis committee, Drs. Larry McIntire and 
Eberhard Voit from Georgia Tech, Dr. Stephen Hanson from OHSU, and particularly Dr. 
William Federspiel from the University of Pittsburgh, who also served as my 
undergraduate advisor and welcomed me into his lab upon my entry to college.   
The bulk of my thesis would not have been possible without Neil Bright and the 
resources of the ChBE Departmental High Performance Computing cluster.  I am 
indebted to Dr. Matthew Corriere for his help with statistical analyses.  I would also like 
to thank Drs. Carla Vossen and Frits Rosendaal for providing us with data from the 
Leiden Thrombophilia Study.  A collective thanks is owed to those with whom I had the 
privilege of working alongside in the Chaikof lab and the MD/PhD program.   
Since childhood, my family has stood behind me without expectation, but with 
utmost confidence in my abilities.  I aspire to be the academic example and mother to 
my children as my mother was to me.  I could write endlessly extolling the contributions 
of my husband, Jeremiah.  Besides unrelenting love, patience, understanding, (and 
technical support), my computer engineer-husband has mastered the art of feigning 
interest and maintaining intelligent conversation about finite element modeling, blood 
coagulation, and clinical medicine.  Finally, but never lastly, I acknowledge my son, 
Linus, who is, and will always be my greatest achievement.
 iv 
 




ACKNOWLEDGEMENTS ............................................................................................... iii 
 
LIST OF TABLES ........................................................................................................... vi 
 
LIST OF FIGURES ........................................................................................................ vii 
 
CHAPTER 1 INTRODUCTION ................................................................................. 1 
1.1. REFERENCES ............................................................................................... 4 
 
CHAPTER 2 BACKGROUND ................................................................................... 5 
2.1. Blood coagulation ........................................................................................... 5 
2.1.1. Regulation of thrombin generation ........................................................... 6 
2.1.2. Threshold response of thrombin formation .............................................. 6 
2.2. The Vascular surface ...................................................................................... 7 
2.2.1. Thrombomodulin ..................................................................................... 8 
2.2.2. Tissue factor ............................................................................................ 9 
2.3. Computational models of blood coagulation ...................................................10 
2.3.1. Fluid phase models of coagulation .........................................................11 
2.3.2. Flow based models of coagulation..........................................................13 
2.3.3. Models of coagulation incorporating spatial parameters .........................15 
2.3.4. Models of fibrinolysis and platelet activation and aggregation .................17 
2.4. Michaelis-Menten reaction kinetics .................................................................18 
2.5. Finite element modeling .................................................................................19 
2.6. REFERENCES ..............................................................................................20 
 
CHAPTER 3 SIMULATED SURFACE-INDUCED THROMBIN GENERATION IN A 
FLOW FIELD  ...........................................................................................................26 
Abstract .....................................................................................................................26 
3.1. Introduction ....................................................................................................26 
3.2. Rationale for model approach ........................................................................27 
3.3. Methods .........................................................................................................28 
3.3.1. Model description ...................................................................................28 
3.3.2. Model assumptions ................................................................................33 
3.3.3. Model implementation ............................................................................35 
3.3.4. System parameters describing surface-induced thrombin generation over 
spatially discrete regions of TF and TM ..................................................................37 
3.3.5. Modeling tandem lesions ........................................................................39 
3.4. Results ...........................................................................................................42 
3.4.1. Thrombin generation increases with increasing TF surface density up to a 
transport limit ..........................................................................................................43 
3.4.2. APC generation increases with increasing TM surface density up to a 
transport limit ..........................................................................................................43 
3.4.3. The model system exhibits threshold responses to tissue factor, 
thrombomodulin, and wall shear rate ......................................................................44 
 v 
3.4.4. Hemophilia A & B increase required levels of tissue factor and reduce the 
rate of thrombin formation ......................................................................................45 
3.4.5. The effectiveness of APC to inhibit the onset of the amplification phase of 
coagulation is determined within the first 3-5 min of the initiation phase .................46 
3.4.6. Extrinsic tenase governs initiation of coagulation, while intrinsic tenase 
governs amplification ..............................................................................................47 
3.4.7. Tissue factor, thrombomodulin, and shear rate dictate the dimensions of 
an effective prothrombotic zone that extends beyond the initiating site of thrombin 
generation ..............................................................................................................47 
3.4.8. Thrombomodulin expression within the intervening regions dictates the 
suppressive interactions that occur between sequential TF sites ............................49 
3.4.9. The sequential interaction of effective prothrombotic zones produced by 
tandem sites results in enhancement of the overall thrombotic response ...............50 
3.5. Discussion .....................................................................................................61 
3.5.1. Computational modeling of blood coagulation ........................................61 
3.5.2. Simulated hemophilias ...........................................................................66 
3.5.3. Atherosclerosis and the importance of interactions between multiple 
lesions 67 
3.5.4. Model limitations and extensions ............................................................69 
3.5.5. Summary ................................................................................................75 
3.6. REFERENCES ..............................................................................................77 
 
CHAPTER 4 SIMULATED THROMBIN GENERATION PROFILES AS A 
PREDICTOR OF THROMBOTIC RISK AMONG PRE-MENOPAUSAL WOMEN ..........84 
4.1. Introduction ....................................................................................................84 
4.2. Methods .........................................................................................................86 
4.2.1. Study populations ...................................................................................86 
4.2.2. Numerical model of thrombin generation ................................................87 
4.2.3. Statistical analysis ..................................................................................90 
4.3. Results ...........................................................................................................92 
4.3.1. Descriptive statistics ...............................................................................92 
4.3.2. Associations between FSTG and thrombosis .........................................94 
4.4. Discussion .....................................................................................................99 
4.4.1. Patient screening and clinical assessment .............................................99 
4.4.2. Assumptions and limitations ................................................................. 101 
4.4.3. A systems-based method to predict thrombosis ................................... 103 
4.5. REFERENCES ............................................................................................ 105 
 
CHAPTER 5 DISCUSSION ................................................................................... 108 
5.1. Summary of major findings ........................................................................... 108 
5.2. Future works ................................................................................................ 109 
5.2.1. Model development .............................................................................. 109 
5.2.2. Population-based studies ..................................................................... 110 
5.3. REFERENCES ............................................................................................ 111 
 
APPENDIX A: Model equations & boundary conditions ............................................... 112 
 
APPENDIX B: Dimensional analysis ............................................................................ 117 
 
APPENDIX C: Annotated MATLAB script for three spatially discrete TF regions ......... 119 
 
 vi 
LIST OF TABLES 
Table 3.1.  Michaelis-Menten kinetic parameters for coagulation and inhibitory reactions 
 30 
 
Table 3.2.  Plasma concentrations of coagulation factors, inhibitors, and related diffusion 
coefficients 32 
 
Table 3.3.  Equilibrium association and dissociation parameters for coagulation and 
inhibitory reactions 34 
 
Table 4.1. Reference plasma concentrations 87 
 
Table 4.2a. Number of participants with FSTGvenous > 10 nM 92 
 
Table 4.2b. Number of participants with FSTGarterial > 10 nM 92 
 
Table 4.3. Descriptive statistics for the entire study population 93 
 
Table 4.4. Univariate models with DVT as outcome 95 
 
Table 4.5. Single factor models adjusted for participant age and OC use 95 
 







LIST OF FIGURES 
Figure 3.1.  Coagulation reaction network described in the computational model. 40 
 
Figure 3.2.  Formulation of a spatially heterogeneous model of surface-induced thrombin 
generation in a flow field. 41 
 
Figure 3.3.  Characterization of transport-limited regimes under arterial flow (500s-1) 52 
 
Figure 3.4.  Threshold response of thrombin to TF site length, TF surface density, and 
TM surface density under simulated arterial flow (500 s-1) 53 
 
Figure 3.5. Threshold response of thrombin generation to TF surface density for normal 
physiologic and hemophiliac conditions. 54 
 
Figure 3.6.  Time course for coagulation systems that lie above or below a prothrombotic 
activation threshold. 55 
 
Figure 3.7.  Factors influencing the length of the EPZ. 56 
 
Figure 3.8.  Effective prothrombotic zone and its dependence on TM surface 
concentration. 57 
 
Figure 3.9.  Additive, intermediate, and suppressive interactions between tandem 
prothrombotic sites. 58 
 
Figure 3.10.  Effect of TF interval on additive and suppressive interactions between 
tandem TF sites. 60 
 
Figure 4.1. Formulation of a spatially heterogeneous model of surface-induced thrombin 
generation in a flow field. 91 
 
Figure 4.2. Venous and arterial FSTG distribution stratified by DVT status. 97 
 
Figure 4.3. Venous and arterial FSTG distribution stratified by OC use. 98 
 
Figure C.1. Boundary number labels.  (1) Inlet, (2) inert entrance region, (3) inert upper 
surface, (4,6,8) TF-expressing regions, (5,7,9) TM-expressing regions, (10) outlet.  The 








Hemostasis is a highly dynamic, tightly regulated, process mediated by both 
cellular components and soluble coagulation factors, which ultimately results in rapid 
and localized clot formation at a site of injury.  Physiologic clotting is essential for control 
of hemorrhage; however, deregulation of coagulation events can lead to thrombotic 
disease and significant clinical outcomes including deep vein thrombosis (DVT), 
pulmonary embolism (PE), myocardial infarction (MI), and stroke.  It is estimated that 
over 200,000 new cases of venous thromboembolism (VTE), which includes both DVT 
and PE, occur each year with a 30-day mortality rate of 30%.  An additional 30% of new 
VTE patients will experience a recurrent thromboembolic event within 10 years.  Within 
the arterial circulation, myocardial infarction is associated with an estimated annual 
incidence of nearly 900,000 new and recurrent attacks and total-mention mortality of 
over 220,000 in 2002.  The annual incidence of ischemic stroke is approximately 
600,000 [1].   
Furthermore, device thrombosis remains a considerable obstacle in the 
development of clinically durable small-diameter vascular prostheses as well as 
permanently implantable biosensors and blood-contacting artificial organs.  Although 1-
year patency rates of expanded polytetrafluoroethylene (ePTFE) prostheses and 
saphenous vein grafts for above knee infrainguinal bypass are similar, by 5 years, up to 
60% of synthetic grafts will occlude or require revision compared with 20% to 30% of 
vein grafts.  This disparity is even greater for bypass to the below knee popliteal artery or 
infrageniculate vessels or in the performance of synthetic arteriovenous dialysis grafts 
when compared with autologous fistulas.  Growing appreciation of the processes 
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underlying coagulation and its regulation has driven the pursuit of bioinspired, 
antithrombogenic biomaterials functionalized with heparin, thrombomodulin, urokinase, 
as well as pharmacologic thrombin inhibitors [2].   
The central hypothesis of this thesis is that a mathematical model of blood 
coagulation will contribute to the understanding of the hemostatic system and its 
disregulation and will therefore be useful as both a diagnostic tool and a design aid.  The 
overall objective is to formulate a finite element model of coagulation that describes 
thrombin generation under defined flow conditions, initiated and modulated by spatially 
discrete regions of surface-bound tissue factor (TF) and thrombomodulin (TM), 
respectively.  In Section I, we describe the model design and reproduce characteristic 
features of thrombin generation under simulated physiologic conditions.  The behavior of 
the model system in response to perturbations in tissue factor and thrombomodulin 
surface densities, tissue factor site dimensions, and wall shear rate is explored.  The 
classic time course characterized by initiation and amplification of thrombin generation is 
recreated, and the existence of threshold-like responses, which have been 
demonstrated in vitro as well as in computational studies [3-11], is illustrated.  Secondly, 
a new parameter, the „effective prothrombotic zone‟, is defined, and its dependence on 
model parameters is described.  It was found that prothrombotic effects may extend 
significantly beyond the dimensions of the spatially discrete site of tissue factor 
expression in both axial and radial directions.  Furthermore, we take advantage of the 
finite element modeling approach to explore the behavior of systems containing multiple 
spatially distinct sites of TF expression in a physiologic model.  Additive prothrombotic 
interactions as well as TM-mediated suppressive interactions between TF sites are 
observed and discussed in the context of coronary artery disease.  In Section II, the 
computational model is applied to assess individualized thrombotic risk from clinical data 
of plasma coagulation factor levels.  We demonstrate a significant association of the 
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systems-based parameter with deep venous thrombosis and propose the use of 
computational methods in combination with biochemical panels to predict 
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2.1. Blood coagulation 
Central to the hemostatic system is the formation of thrombin.  The endpoint of a 
cascade of reactions triggered by exposure of subendothelial tissue factor (TF), thrombin 
converts fibrinogen to fibrin, activates platelets, and is involved in a number of other 
mitogenic and inflammatory pathways [1].  The clotting 'cascade' involves a series of 
serine protease reactions converting inactive zymogens to active enzymes.  Coagulation 
is traditionally divided into two parallel pathways, the intrinsic and extrinsic pathways, 
which converge on a common pathway.  The intrinsic pathway is defined by components 
that reside entirely within the intravascular system.  Specifically, factor XII is 
autoactivated upon contact with negatively charged surfaces, including glass and many 
biomaterials, in a reaction involving high molecular weight kininogen (HMWK) and 
prekallikrein.  Factor XIIa activates factor XI, and factor XIa, in turn, activates factor IX.  
The complexation of factors IXa and VIIIa on a phospholipid surface, forming 'intrinsic 
tenase', results in the generation of activated factor X.  It is the extrinsic, or tissue factor 
pathway, however, that is generally accepted as the principal initiating pathway of 
coagulation in vivo.  Exposure of subendothelial TF to the bloodstream and subsequent 
formation of the TF/ VIIa complex leads to the activation of both factors IX and X.  The 
generation of factor Xa by either intrinsic (IXa/ VIIIa) or extrinsic (TF/ VIIa) tenase leads 
to the assembly of prothrombinase (Xa/Va), which cleaves prothrombin (factor II) to 
thrombin (IIa).  Amplification of thrombin generation is achieved through positive 
feedback of thrombin to activate factors V and VIII.  Key themes relevant to the 
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coagulation cascade are the sequential reaction of zymogen-enzyme pairs, the 
requirement for cofactors, and the calcium-dependent, membrane-mediated coordination 
of enzyme complexes [2-4].   
 
2.1.1. Regulation of thrombin generation 
Physiologic regulators of thrombin include the protein C pathway, antithrombin III, 
and tissue factor pathway inhibitor (TFPI).  The protein C pathway begins when thrombin 
binds to thrombomodulin, consequently redirecting the function of thrombin towards 
anticoagulant activity.  Activated protein C inactivates the cofactors Va and VIIIa in a 
protein S-dependent manner [2-4].  Antithrombin III (ATIII) is a serine protease inhibitor 
that forms a 1:1 molar complex with factors IXa, Xa, and thrombin.  The affinity of ATIII 
for its substrates is greatly enhanced in the presence of physiologic surface 
glcyosaminoglycans or pharmacologic heparin [5].  Finally, TFPI is a trivalent Kunitz-type 
serine protease inhibitor synthesized by endothelial cells, which inhibits factor Xa 
through binding with its second Kunitz domain and inactivates TF/ VIIa through binding 
with its first Kunitz domain [6, 7].  Thus, TFPI acts in a two-step process to form a 
quaternary complex with factor Xa and TF/ VIIa, neutralizing the tissue factor stimulus [8, 
9].  The protein C pathway and TFPI pathway are classic examples of negative 
feedback, requiring the presence of thrombin and factor Xa, respectively, while ATIII acts 
primarily as a scavenger for activated enzymes.  In the presence of TFPI, ATIII has been 
shown to play a critical role in regulating low-level basal activation of coagulation by TF 
[10-12].   
 
2.1.2. Threshold response of thrombin formation 
During the initiation phase of coagulation, very low levels of thrombin are 
produced.  During this phase, inhibitors may dampen the thrombin response and prevent 
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amplification and full activation of the coagulation cascade; this is considered a 'sub-
threshold' thrombin response.  However, when the capacity of these inhibitors is 
overwhelmed by the magnitude of the thrombogenic stimulus, thrombin levels cross an 
activation threshold and rapid amplification of thrombin generation occurs.  The 
combination of multiple long- and short-range positive feedback loops and 
complementary inhibitory mechanisms results in tight regulation of coagulation 
characterized by rapid, „all-or-none‟ behavior [12, 13].  Ismagilov et al. have published a 
number of experimental studies characterizing coagulation thresholds with respect to TF 
patch size, wall shear rate, and spatial distribution of TF sites in both flow and non-flow 
environments [14-16].  Several computational groups have reported on the „on/ off‟ 
response of coagulation to parameters such as TF and factor Xa stimulus [17, 18], TF 
patch size [19, 20], inhibitor concentrations and associated kinetic parameters [17], as 
well as blood flow [19, 20].  Threshold-like behavior was simulated in model systems as 
simple as two zymogen-enzyme pairs in a positive feedback loop with inhibition [21].  
 
2.2. The Vascular surface 
The surface of the blood vessel wall serves several functions in the regulation 
and promotion of blood coagulation.  The 'resting' endothelium synthesizes and presents 
a number of antithrombogenic molecules including heparan sulfate proteoglycans, ecto-
adenosine diphosphatase, prostacyclin, nitric oxide, and thrombomodulin [22-27].  In 
response to various stimuli, including inflammatory mediators, hypoxia, oxidative stress, 
and fluid shear stress, the cell surface becomes 'activated' and serves to organize 
membrane-associated enzyme complexes of coagulation.  Additionally, the occupation 
of cell surface receptors for procoagulant products such as factor Xa and thrombin leads 
to a variety of cellular responses including mitogenic, chemoattractant, and yet 




Thrombomodulin (TM) is a 60kD type I transmembrane protein expressed on the 
luminal surface of vascular endothelium and smooth muscle cells.  TM switches off all 
known procoagulant functions of thrombin by occupying the functionally important 
exosite I on thrombin [34], and instead channels the catalytic power of the enzyme into 
anticoagulant activities, specifically enhancing the rate of thrombin inactivation by ATIII 
[35] and significantly accelerating the ability of thrombin to activate protein C (>1,000-
fold).  Once generated, activated protein C (APC) is one of the slowest of the serine 
proteases to be inactivated and cleared from the circulation with a half-life of 20 min .  
APC, together with protein S, inactivates factors Va and VIIIa, thereby preventing further 
amplification of factor Xa and thrombin [36-38].  It is well established that patients with 
protein C or protein S deficiency, as well as those with resistance to APC are prone to 
develop thromboembolic events [34].   
Complete ablation of the TM gene causes embryonic lethality in mouse models 
[39].  However, mutations which severely reduce the capacity of TM to activate protein C 
cause increased fibrin deposition in selected organs [40], and endothelial cell-specific 
loss of TM leads to early onset thrombosis in mice [41].  In human studies, a 
heterozygous point mutation in the TM gene (G1456T) affecting the amino acid 
sequence located between the transmembrane domain and the sixth epidermal growth 
factor-like domain was identified in a 45-year-old man who presented with pulmonary 
embolism [42].  A heterozygous substitution of G127 to A was first detected in a 42-year-
old woman who presented with sagittal sinus thrombosis [43] and has been associated 
with an increased risk of myocardial infarction before the age of 50 [44].  In a screen of 
104 patients admitted for myocardial infarction, three distinct polymorphisms in the 5' 
promoter region of the TM gene were identified in five patients [45].  Finally, a mutation 
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consisting of both a silent base substitution (G1686C) and a base insertion (insT1689), 
which resulted in elongation of the intracellular domain and reduced trafficking to the cell 
surface, was associated with myocardial infarction in a thrombophilic family [46].     
Thrombomodulin expression has been shown to be upregulated by a number of 
factors including cAMP [26, 27], retinoic acid [28-30], vitamin D [47], as well as 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins [48-51], and 
autintricarboxylic acid [52]. Inflammatory mediators, specifically TNF-α [53-57], 
interleukin-1 [53, 58, 59], transforming growth factor (TGF- ) [60], and bacterial 
endotoxin [61], suppress TM expression in patients with severe bacterial sepsis, adult 
respiratory distress, and multiple organ system failure [62].  Additionally, hypoxia has 
been shown to downregulate TM expression [63].   
 
2.2.2. Tissue factor 
Tissue factor (TF) is a 47kD transmembrane protein whose primary role in blood 
coagulation is to bind factor VIIa and participate in the activation of factor X, thus 
initiating thrombin generation.  Cell-associated TF is expressed in high levels within the 
vasculature of vital organs such as the skin, lungs, brain, heart, kidneys, testis, uterus, 
and placenta.  In contrast, skeletal muscles and joints have relatively low levels of TF 
and appear to rely more heavily on the intrinsic pathway of coagulation for hemostasis 
[64, 65].  In healthy vessels, TF is found on adventitial fibroblasts and smooth muscle 
cells, allowing for rapid initiation of coagulation upon vascular injury [66].  In a mouse 
model of laser-induced vascular injury, Falati et al. [67] demonstrated using confocal 
intravital imaging that while TF was found throughout the growing thrombus, TF 
remained most concentrated at the interface between the vessel wall and the thrombus.  
Additionally, immunohistochemical staining of atherosclerotic lesions has shown 
significant levels of TF within the foam cells adjacent to the cholesterol clefts and within 
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the necrotic cores of plaque lesions.  Upon rupture of the fibrous cap, large amounts of 
TF are exposed to the bloodstream, precipitating thrombus formation.  It is suggested 
that the deposition of TF within the matrix of the atherosclerotic plaque is responsible for 
the hyperthrombotic state of atherosclerotic vessels leading to serious clinical sequelae 
including acute coronary syndrome and sudden cardiac death [66, 68, 69].   
TF expression by endothelial cells and monocytes may be induced by a number 
of inflammatory mediators including tissue necrosis factor (TNF-α), interleukin-1 (IL-1), 
histamine, endotoxin, oxidized lipoproteins, and heme [68, 70-72].  C-reactive protein 
enhances TF expression with concomitant decreases in tissue factor pathway inhibitor 
(TFPI) expression in vascular smooth muscle cells [73].  In contrast, the anti-arrhythmia 
drug amiodarone was found to inhibit TF protein translation and reduce carotid artery 
thrombosis in a mouse photochemical injury model [74].   
Circulating TF has gained recent attention although its role in physiology has yet 
to be fully established.  Alternatively spliced soluble tissue factor has been identified with 
retained procoagulant activity.  This isoform of TF is incorporated into growing thrombi 
when exposed to phospholipids and has been induced from endothelial cells by 
inflammatory mediators [75, 76].  Additionally, TF incorporated within the membrane of 
circulating microparticles shed from a variety of cell types has been studied in relation to 
coronary artery disease, inflammation, and cardiopulmonary bypass [77-80].   
 
2.3. Computational models of blood coagulation 
Mathematical models of blood coagulation have been developed with varying 
degrees of complexity for many different purposes.  Several models restrict their 
analysis to reaction kinetics of all or part of the intrinsic, extrinsic, and common 
pathways, neglecting the role of blood flow.  Those that have taken the effects of blood 
flow into account have used a simple compartmental modeling approach, which relies 
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heavily on the assumption of spatial homogeneity in the direction of flow.  Finite element 
models of surface-bound reactions under flow have so far have been limited in the 
number of reactions considered.   Recently, spatially heterogeneous models, which 
describe the growth of clot formation in space or discrete 'patches' of surface 
expression, have been developed, though most do not include convective effects.  In this 
section, we review models of blood coagulation that have been conceived for 
applications ranging from the study of coagulation dynamics and phenomena to the 
simulation of clinical diagnostic values.   
 
2.3.1. Fluid phase models of coagulation 
Nesheim et al. explored the properties of prothrombinase assembly and activity 
within an interface shell surrounding phospholipid vesicles in solution in a steady-state, 
two-phase model.  The distribution of substrate and enzyme between the bulk and shell 
phases was used to rationalize the apparent inhibition by excess enzyme, substrate, and 
phospholipid [81].  Willems et al. studied a dynamic model of thrombin generation in 
plasma describing 14 pro- and anti-coagulant reactions, including inhibition of 
coagulation by activated protein C, antithrombin III, and exogenous hirudin.  The 
stimulus was a transient pulse of factor Xa, and a threshold response to this stimulus 
was reported that was dependent on ATIII inactivation of thrombin and factor Xa [18].  
Jones and Mann developed a more complex model of the dynamics of coagulation, 
which included the activation of factors IX, X, V, VIII, and thrombin, as well as the 
assembly of the phospholipid-associated enzyme complexes, intrinsic tenase (IXa/ VIIIa) 
and prothrombinase (Xa/Va).  Thrombin generation was initiated by TF/VIIa in 
concentrations ranging from 5 pM to 5 nM [82].  The group later extended the model to 
include a number of additional substrate interactions and positive feedback mechanisms, 
and significantly, incorporated the coagulation inhibitors, tissue factor pathway inhibitor 
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(TFPI) and antithrombin III (ATIII), resulting in a model system describing the fates of 34 
species.  The major finding of the study was the threshold-like dependence of thrombin 
generation on the concentrations of TF, ATIII, and TFPI [17].  Furthermore, the 
numerical simulations were used to study the role of surface-localized versus circulating 
TF during the initiation, propagation, and termination phases of coagulation [83].  The 
Hockin model was also recently used to predict thrombin generation curves from clotting 
factor levels collected from the control population of the Leiden Thrombophilia Study 
(LETS) [84].  Jesty and colleagues considered, both analytically and numerically, the 
threshold behavior that resulted from representative systems ranging from an auto-
activating zymogen-enzyme pair, to systems of two or four zymogen-enzyme pairs with 
multiple positive feedback mechanisms subject to irreversible, first-order inactivation.  In 
the presence of inhibition, all systems exhibited threshold behavior, which was 
modulated by changes in initial concentrations of active enzymes, enzyme kinetics, the 
presence of multiple positive feedback loops, membrane patch size, and in later models, 
flow [19, 21, 85].  Similarly, Bungay et al. demonstrated the dependence of a threshold 
response on the availability of phospholipid surfaces [86, 87].   
Several others have mathematically described the kinetics of the extrinsic and 
intrinsic pathways in solution to simulate the laboratory assays prothrombin time (PT) 
and activated partial thromboplastin time (aPTT), respectively, and to evaluate the 
sensitivities of the systems to clotting factor deficiencies [88-91].  Leipold et al. 
developed a model of the tissue factor pathway as a design aid for the development of 
exogenous serine protease inhibitors [92].  In contrast, Guo et al. focused on the 
reactions of the contact, or intrinsic pathway, to study parameters relevant to material-
induced thrombosis, including procoagulant surface area [93].   
Alternative approaches to modeling the coagulation cascade have been pursued 
including the use of stochastic activity networks to represent the intrinsic, extrinsic, and 
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common pathways through fibrin formation [94] and a kinetic Monte Carlo simulation of 
TF-initiated thrombin generation [95].   
Generally, fluid phase models of the kinetics of coagulation are both 
computationally and experimentally less complex.  As such, the computational models 
are able to incorporate a large number of species and their reactions, and empirical data 
is often available for regression analysis and model validation.  The range of complexity 
and motivations for these models is wide, and the models have been used to describe 
various phenomena including the 'all-or-none' threshold behavior of thrombin generation.  
However, the role of blood flow in coagulation is well recognized in promoting the 
delivery of substrates to the vessel wall and in regulating the thrombin response by 
removing activated clotting factors. 
 
2.3.2. Flow based models of coagulation 
In 1990, Basmadjian presented a mathematical analysis of the effect of flow and 
mass transport on a single reactive event at the vessel wall and consequently laid the 
foundation for the first flow-based models of coagulation.  It was proposed that for 
vessels greater than 0.1 mm in diameter, reactive events at the vessel wall could be 
adequately described by the assumption of a concentration boundary layer very close to 
the reactive surface, within which the majority of concentration changes took place.  The 
height of the boundary layer and the mass transfer coefficient that described transport to 
and from the vessel wall were shown to stabilize on a time scale much shorter than the 
time scale over which concentration changes were empirically observed.  Thus, the 
vascular space could be divided into two compartments, a boundary volume and a bulk 
volume, and furthermore, changes within the bulk phase could be considered negligible, 
thereby reducing the previously intractable problem to a pseudo-one compartment 
model described by a system of ordinary differential equations [96].  Baldwin and 
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Basmadjian subsequently published a limited model of six reactions, including two 
positive feedback reactions and two inhibitory reactions, of the common pathway of 
coagulation triggered by exogenous factor IXa under flow.  As a consequence of the 
definition of the mass transfer coefficient, the kinetic parameters were dependent on the 
boundary layer height.  Furthermore, the model did not explicitly account for intrinsic 
tenase or prothrombinase formation, but rather derived a rate expression for reaction in 
the presence of a cofactor.  The major finding of the study was the predicted effect of 
increased mass transport to enhance thrombin generation by decreasing the induction 
time up to a critical mass transfer rate, beyond which transport significantly decreased 
peak thrombin levels thereby reducing overall thrombin production [97].  Kuharsky and 
Fogelson formulated a more comprehensive, pseudo-one compartment model of tissue 
factor-initiated coagulation under flow, which included the description of 59 distinct fluid- 
and surface-bound species.  In contrast to the Baldwin-Basmadjian model, which 
defined a mass transfer coefficient as a rate of transport to the vessel surface, the 
Kuharsky-Fogelson model defined the mass transfer coefficient as a rate of transport 
into the boundary volume, thus eliminating the dependence of kinetic parameters on 
transport parameters.  The computational study focused on the threshold response of 
thrombin generation to the availability of membrane binding sites.  Additionally, the 
model suggested that adhered platelets may play a role in blocking the activity of the TF/ 
VIIa complex [98].  Fogelson and Tania later expanded the model to include the protein 
C and TFPI pathways [99].  One consequence of defining a boundary, or 'shell', volume 
is that surface-bound species, such as TF, are assumed to be uniformly distributed 
through the volume, and thus their effective concentrations, with units of moles per 
volume, become a function of flow rate.  Furthermore, these pseudo-one compartment 
models, like the fluid phase models, assume spatially homogenous, or well mixed, 
compartments.  The assumption breaks down as the dimensions of the boundary 
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volume increase, e.g. at low shear rates and for large reaction areas, due to the potential 
for substrate depletion and product accumulation at the surface or at upstream sites.  
Relevant to hemostasis, the surface of the vascular wall is highly non-uniform with 
respect to the protein expression and phosholipid composition, features which are 
important for the localization of thrombus formation to injury sites.   
An alternative approach to modeling surface-associated reactions under flow 
uses finite element method (FEM), which is a technique for solving partial differential 
equations by dividing the vascular space into a finite number of discrete elements.  Hall 
et al. used FEM to simulate factor X activation over a surface presenting TF in a parallel 
plate flow reactor.  The steady state model was defined by the convection-diffusion 
equation and Michaelis-Menten reaction kinetics at the surface.  The computational 
results were compared to experimental data for the generation of factor Xa by cultured 
rat vascular smooth muscle cells expressing TF.  Based on discrepancies between 
numerical and experimental studies, the authors hypothesized the catalytic activity of the 
TF/ VIIa complex may be shear-dependent [100].  Towards the overall objective of 
developing an antithrombogenic biomaterial, Tummala and Hall studied the kinetics of 
factor Xa inhibition by surface-immobilized recombinant TFPI under unsteady flow 
conditions [101].  Similarly, Byun et al. investigated the association and dissociation 
kinetics of ATIII inactivation of thrombin accelerated by surface-immobilized heparin 
under steady flow conditions [102].  To date, finite element models that detail surface-
bound reactions under flow have been restricted no more than a single reaction 
catalyzed by a single surface-immobilized species.   
 
2.3.3. Models of coagulation incorporating spatial parameters 
Ataullakhanov and colleagues developed mathematical models to describe the 
spatial dynamics of clot formation in the direction perpendicular to the vessel wall [103, 
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104].  In later reports, coagulation is initiated by a monolayer of TF-expressing cells and 
propagates into the bulk of plasma.  Extrinsic, intrinsic, and protein C pathways were 
represented by 27 partial differential equations.  Major findings include the roles of these 
specific coagulation pathways in the initiation, amplification, and termination phases of 
coagulation.  It was observed that coagulation near the activating surface was 
determined by TF/VIIa catalyzed factor Xa production, which was rapidly inhibited close 
to the wall.  In contrast, factor IXa diffused farther from the surface, and thus factor Xa 
generation and clot formation away from the reactive wall was dependent on intrinsic 
tenase (IXa/ VIIIa) activity.  Additionally, the concentration wave of thrombin propagated 
away from the activation zone at a rate which was dependent on the efficiency of 
inhibitory mechanisms.  Experimental and 'virtual' addition of plasma-phase 
thrombomodulin resulted in dose-dependent termination of thrombin generation and 
provided evidence of spatial localization of clot formation by TM with final clot lengths of 
0.2-2 mm under diffusive conditions [105, 106].  These studies provide an interesting 
analysis of the roles of specific factors in relation to space due to diffusive effects, but 
neglect the essential role of blood flow in the transport analysis.  Additionally, the spatial 
dynamics of clot localization by thrombomodulin would likely be affected by restricting 
the inhibitor to its physiologic site on the vessel surface.     
Ismagilov et al. have studied the threshold response of coagulation to various 
spatial parameters, both in vitro and computationally, in microfluidic systems of TF-
patterned phospholipid surfaces [14].  Numerically, initiation of a representative 
autocatalytic system by different sized and shaped patches was simulated using a finite 
element model, which defined three reactions and diffusion.  The reaction 'modules' 
represented the kinetics of: 1) activation by the stimulus patch, corresponding to TF-
mediated initiation of coagulation, 2) autocatalytic production of the activator in solution, 
representing the positive feedback mechanisms of coagulation, and 3) linear 
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consumption of the enzyme product in solution.  A threshold response to the size of the 
TF patch was empirically and numerically shown to follow a simple scaling relationship 
based on the ratio of the rate of diffusion off of the patch to the rate of generation of the 
activating species [20].  Shape was also demonstrated to be a determinant of 
coagulation activation, with narrow rectangles and stars remaining below an activation 
threshold and circular, square, and wide rectangular patches resulting in significantly 
amplified product generation [107].  Furthermore, Kastrup et al. demonstrated that 
spatial distribution of TF patches, rather than total surface area, dictated the overall 
response of the system [16, 108].  Runyon et al. described the propagation of clotting 
from an initiating microchannel into a perpendicularly oriented channel with flowing 
plasma.  In small microchannels, clotting was shown to be inhibited by surface-bound 
inhibitors, specifically TM, while in larger microchannels, the threshold response of 
clotting was regulated by the shear rate in the cross-flowing channel [109].  The simple 
numerical experiments served primarily to confirm experimental observations, and with 
the exception of the cross-flow channel, no convective effects were considered.   
 
2.3.4. Models of fibrinolysis and platelet activation and aggregation 
An important, yet still separate, area of modeling hemostasis and thrombosis 
involves the mechanical and rheological aspects of fibrinolysis and platelet activation 
and aggregation.  Anand et al. have described some partial models of the formation and 
lysis of fibrin clots, including models of the extrinsic and fibrinolytic pathways in the 
absence of flow and continuum mechanical models of loose fibrin clots in a flow field 
[110, 111].  Fogelson and colleagues have modeled the adhesion and cohesion of 
activated platelets as elastic links which can influence the surrounding fluid motion.  
Simulations of platelet thrombus growth in small vessels demonstrated that shear stress 
exerted by the viscous fluid could modulate thrombus growth and cause remodeling of 
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thrombus shape [112].  Filipovic et al. described the motion, collision, adhesion, and 
cohesion of resting and activated platelets using dissipative particle dynamics (DPD)  in 
which discretized blood components interact through conservative, dissipative, 
attractive, and random forces [113].   
 
2.4. Michaelis-Menten reaction kinetics 
Michaelis-Menten kinetics are often used to describe the rate of biochemical 
reactions catalyzed by enzymes and are appropriate approximations in the absence of 
intermediate or product inhibition and in the absence of cooperativity.  Leonor Michaelis 
and Maud Menten postulated that the enzyme (E) and substrate (S) were in fast 
equilibrium with the enzyme-substrate complex (ES), and that the enzyme-substrate 
complex dissociated irreversibly to yield free enzyme and product (P) (Eq. 2.1).  
Derivation of the Michaelis-Menten rate law (Eq. 2.2), which relates the initial reaction 
rate to the substrate concentration, relies on a quasi-steady state approximation for the 
enzyme-substrate intermediate [114].   
Thus, reactions which are said to follow Michaelis-Menten kinetics are 
characterized by two parameters, kcat, or the turnover number, and KM, the Michaelis 
constant.  The Michaelis constant is equal to the substrate concentration at which the 
reaction rate is half of its maximum value.  KM is related to, but does not fully describe, 
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2.5. Finite element modeling 
Finite element method (FEM) is a numerical technique for solving partial 
differential equations.  Originally proposed in the 1940s to approach structural analysis 
problems in civil engineering, FEM now finds application in a wide variety of disciplines.  
The computational method relies on mesh discretization of a continuous domain which 
subdivides the space into a finite number of 'elements'.  The physics of each element are 
defined by its own set of physical properties and boundary conditions, and the 
simultaneous solution of the equations describing the individual elements approximate 
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CHAPTER 3  
 
 
SIMULATED SURFACE-INDUCED THROMBIN GENERATION IN A FLOW FIELD 
Abstract 
A computational model of blood coagulation is presented with particular 
emphasis on the regulatory effects of blood flow, spatial distribution of tissue factor (TF), 
and the importance of the thrombomodulin (TM)-APC inhibitory pathway.  Significantly, 
we demonstrate that an „effective prothrombotic zone‟ (EPZ) may be defined that 
extends well beyond the dimensions of injury.  The size of this zone is dependent not 
only on the concentrations of all reactive species, but also on the dimensions of TF 
expression, the densities of surface molecules, and the characteristics of the flow field.  
In the case of tandem sites of TF, the relationship between the magnitude of the EPZ 
and the interval distance between TF sites dictated the net response of the system.  
Multiple TF sites, which individually failed to activate the coagulation pathway, were 
shown to interact in an additive manner to yield a prothrombotic system.  Furthermore, 
activation of the TM-APC pathway in the regions between sites of TF downregulated the 
thrombin response at subsequent TF sites.  The implications of prothrombotic effects 
which extend downstream beyond the discrete site of injury to interact with subsequent 
lesions are critical given the systemic nature of atherosclerotic disease.   
 
3.1. Introduction 
Blood coagulation is a highly dynamic, nonlinear reaction network that is 
characterized by the activation and amplification of circulating zymogens, several 
surface-associated enzyme complexes, and positive and negative feedback loops.  The 
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clotting 'cascade' involves a series of serine protease reactions converting inactive 
zymogens to active enzymes.  Coagulation is traditionally divided into two parallel 
pathways, the intrinsic and extrinsic pathways, which converge on a common pathway.  
However, it is widely accepted that the extrinsic pathway is principal initiating pathway of 
coagulation in vivo.  Exposure of subendothelial tissue factor (TF) to the bloodstream 
and subsequent formation of the TF/VIIa complex leads to the activation of both factors 
IX and X.  The generation of factor Xa by either intrinsic (IXa/VIIIa) or extrinsic (TF/VIIa) 
tenase leads to the assembly of prothrombinase (Xa/Va), which cleaves prothrombin 
(factor II) to thrombin (IIa).  Amplification of the cascade is achieved through positive 
feedback of thrombin to activate factors V and VIII [1-3].  Regulators of thrombin 
generation include the thrombin- and thrombomodulin (TM)-dependent protein C 
pathway, factor Xa-dependent tissue factor pathway inhibitor (TFPI), and the multi-
substrate serine protease inhibitor, antithrombin III (ATIII) [1-6].  Additionally, blood flow 
serves as a critical regulator of thrombosis by removing activated enzymes from the site 
of reactivity [7].  The temporal and spatial dynamics of coagulation under flow are 
complex and mathematical modeling provides a means for the systematic study of 
individual components and their roles in promoting or regulating clot formation.     
 
3.2. Rationale for model approach 
Mathematical models of blood coagulation have been developed with varying 
degrees of complexity and for applications including, but not limited to, the study of 
coagulation dynamics and phenomena, pharmacologic and biomaterial development, 
and the simulation of clinical diagnostic values.  Generally, fluid phase models of the 
kinetics of coagulation are both computationally and experimentally less complex.  As 
such, computational models are able to incorporate a large number of species and their 
reactions, and empirical data is often available for regression analysis and model 
 28 
validation.  However, the essential role of blood flow in promoting the delivery of 
substrates to the vessel wall and in regulating the thrombin response by removing 
activated clotting factors is well recognized.  The major limitation of existing pseudo-one 
compartment models of coagulation under flow [8, 9], in which the vascular space is 
divided into bulk and a boundary volumes, is the assumption of spatially homogenous, or 
well mixed, plasma compartments.  This assumption breaks down as the dimensions of 
the boundary volume increase, such as that which would occur at low shear rates and 
for large reaction areas, due to the potential for substrate depletion and product 
accumulation at the surface or at upstream sites.  In contrast, while models incorporating 
spatial effects have recently been reported [10-12], most describe only reaction and 
diffusion and do not include convective effects.   
A finite element model does not require the assumption of spatial homogeneity 
and permits the definition of a flow model of thrombin generation that accounts for 
distinct sites of tissue factor (TF) and thrombomodulin (TM) surface expression.  
Uniquely, spatial parameters quantifying the localization or propagation of thrombin 
formation, in both vertical and longitudinal directions, may be defined.  To date, finite 
element models that detail surface-bound reactions under flow have been restricted to 
no more than a single reaction catalyzed by a single surface-immobilized species bound 
to a cofactor [13-15].  We present the first comprehensive model of thrombin generation 
under flow conditions characterized by distinct sites of coagulation initiation and 
regulation.   
 
3.3. Methods 
3.3.1. Model description 
Herein, we describe a finite element model of thrombin generation under defined 
flow conditions, initiated and modulated by spatially discrete regions of surface bound 
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tissue factor and thrombomodulin, respectively.  The model incorporates fluid phase and 
surface-associated reactions of the extrinsic, intrinsic, and common pathways, as well as 
three inhibitory pathways (Figure 3.1).  The spatially heterogeneous model describes 
coagulation events that occur following tissue factor exposure at a discrete upstream 
site, as well as related mechanisms that regulate thrombin generation, including those 
mediated by an intact endothelium, represented as a thrombomodulin-containing surface 
(Figure 3.2A).  Specifically, we assume that the coagulation cascade is initiated by 
binding of factor VIIa to tissue factor, leading to the formation of extrinsic tenase.  
Generation of factor Xa leads to activation of factors V and VII.  The resultant surface-
associated complex, Xa/Va, or prothrombinase, cleaves prothrombin to thrombin, which 
by activating factors V and VIII serves as a positive feedback mediator.  Generation of 
factor VIIIa, in association with IXa, affords intrinsic tenase, or IXa/VIIIa.  We assume 
that factor IXa is generated solely by TF/VIIa without participation of intrinsic pathway 
factors XI and XII.   
Three major reaction pathways that serve to inhibit thrombin generation are 
included in the model system - antithrombin III (ATIII), tissue factor pathway inhibitor 
(TFPI), and the protein C pathway.  ATIII serves to inactivate factors IXa, Xa, and 
thrombin.  Tissue factor pathway inhibitor is incorporated as an inhibitor of TF/VIIa 
through a two-step process, whereby TFPI binds to Xa followed by its reversible 
association with TF/VIIa.  Finally, we account for the production of activated protein C, 
which inactivates factors Va and VIIIa.  Table 3.1 summarizes all model reactions and 
the kinetic parameters and distinguishes between surface-bound reactions and those 
that occur both in the fluid phase and at the blood-vessel wall interface. 
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Table 3.1.  Michaelis-Menten kinetic parameters for coagulation and inhibitory reactions 
No. 
 











1 Activation of factor X by TF/VIIa S 1.2 0.45 [22] 
2 
Conversion of prothrombin by 
Va-Xa 
S 33 0.21 [23] 
3 
Activation of protein C by 
thrombin-TM 
S 5.58 0.7 [24] 
4 
Inactivation of factors Va and 
VIIIa by APC 
S 0.58 0.025 [25] 
5 Activation of factor IX by TF-VIIa S 0.34 0.17 [26] 
6 
Activation of factor VIII by 
thrombin 
F 0.9 0.20 [27, 28] 
7 
Activation of factor X by VIIIa-
IXa 
S 20 0.16 [29] 
8 
Activation of factor V by 
thrombin 
F 0.23 0.072 [30] 
9 
Activation of factor VII by factor 
Xa 
F 5.0 1.2 [29] 
10 
Activation of factor V by factor 
Xa 
S 0.046 0.01 [30] 
11 
Activation of factor VII by 
thrombin 
F 0.061 2.7 [31] 
 
 
The reaction area of interest is modeled as a two-dimensional flow field of length, 
L, and half-height, B, with upper and lower inert and reactive surfaces, respectively.  
Steady, one-dimensional, parabolic flow, which is algebraically defined, is assumed (Eq. 
3.1).  In contrast to previous models of surface-induced coagulation, mass transfer 
approximations are not used to describe transport of reactants to the surface.  Equation 
3.2 describes convective-diffusive transport of species, i, with accumulation and 
convective terms on the left-hand side and diffusive and reaction terms on the right-hand 




where x and y are parallel and perpendicular to the reactive wall, respectively, y=0 is 
defined at the reactive surface, u(y) is the fluid velocity in the x-direction as a function of 
y, B is the half-height of the chamber,  is wall shear rate, ci is the concentration of 
species, i, t is time, Di is the diffusion coefficient of species, i, and R is the rate of 
production in the solution phase.   
All fluid-phase zymogen and enzyme concentrations are initially set to zero.  The 
surface density of tissue factor and thrombomodulin remain constant and, at the outset, 
both are free of bound cofactors. Convective flux transports zymogens into the flow field 
at constant inlet concentrations equal to mean physiologic values.  Initial conditions 
assumes that 1% of factor VII circulates as VIIa [16].  Diffusion transports coagulation 
factors to the lower reactive surface, where reaction kinetics define flux boundary 
conditions.  Table 3.2 summarizes inlet concentrations, molecular weights, and 
diffusivities for all coagulation factors [1, 16-18].  Moderate hemophilias A and B were 
defined at 5% of the normal plasma concentration of factors VIII and IX, respectively.  
Diffusion coefficients were calculated from molecular weights according to Young et al. 
[19].   
The reactive boundary is divided into localized upstream TF and downstream TM 
regions.  The primary analysis was performed assuming a 10 mm entrance region, 2 mm 
TF region, and a 34 mm TM region.  The length of the TF region is similar in dimension 
to that of a ruptured coronary plaque or the interface between a vascular graft and host 










Table 3.2.  Plasma concentrations of coagulation factors, inhibitors, and related diffusion 
coefficients 





(x 10-7 cm2/s) 
Ref. 
Prothrombin 1400 72 6.21 [1] 
Thrombin -- 36.7 7.78 -- 
Factor V 20 330 3.74 [1] 
Factor Va -- 168 4.69 -- 
Factor VII 10 50 7.02 [1] 
Factor VIIa 0.1 50 7.02 [16] 
Factor VIII 0.7 170 4.67 [1] 
Factor VIIIa -- 166 4.70 -- 
Factor IX 90 55 6.80 [1] 
Factor IXa -- 45 7.27 -- 
Factor X 170 58.9 6.64 [1] 
Factor Xa -- 46 7.22 -- 
Protein C 60 62 6.53 [1] 
Activated protein C -- 56.2 6.75 -- 
Antithrombin III 2400 58 6.68 [17] 
TFPI 2.5 34 7.98 [18] 
TFPI-Xa 0 80 6.00 -- 
 
† Calculated from molecular weight according to Young et al. [19]. 
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3.3.2. Model assumptions 
Reactive surface.  A number of simplifying assumptions were made with respect 
to surface-bound species and reactions.  The model defines discrete regions of TF or 
TM expression, but otherwise does not discriminate between subendothelium, resting 
endothelium, activated endothelium, or platelet membrane surfaces.  TF and TM surface 
expression is assumed constant over all time points.  TF only binds factor VIIa and not 
factor VII.  Activation of factor VII is assumed to occur in the fluid phase only for 
computational simplicity.  The model assumes that phospholipid conditions promote 
surface-associated enzyme complex assembly, or in other words, that membrane-
binding sites are in excess.  Surface complexes, such as prothrombinase (Xa/Va), are 
assumed to be generated through a bimolecular reaction between two solution phase 
species spatially localized at y=0.  For simplicity, the assembly of these complexes is 
assumed to occur in one step.  Lateral diffusion along the reactive surface is considered 
negligible compared to transport by flow along the direction parallel to the surface. 
Kinetic parameters.  Serine protease activation involves one or more cleavage 
events and is therefore considered irreversible.  All reactions are assumed to follow 
Michaelis-Menten kinetics.  Furthermore, the capacity of enzymes, in the absence of 
respective cofactors, to convert primary substrates is considered negligible.  For 
example, conversion of prothrombin to thrombin by Xa/Va is 105-fold faster than Xa 
alone [21].  Only the former reaction is considered.  Kinetic parameters were obtained 
from the experimental literature of isolated reaction systems (Tables 3.1 and 3.3) with 
preference given to studies deemed most relevant with respect to substrate and enzyme 
concentrations within the physiologic range, the presence of appropriate cofactors such 
as phospholipid surfaces and calcium, where applicable, and method of measurement 
[5, 22-34].  In the cases where only equilibrium binding constants, Kd, were reported, ka 
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was set to the diffusional limit, 108 M-1 s-1, and kd was calculated (kd = Kd × ka).  
Association and dissociation reactions are reversible except where noted.   
 
 














Enzymatic complexes † 
1 Factor VIIa TF 100 0.06 [32] 
2 Factor Xa Factor Va 100 0.01 [33] 
3 Thrombin TM 100 0.01 [24] 
4 Factor IXa Factor VIIIa 100 0.01 [33] 
Inhibitory reactions 
5 Thrombin ATIII 6.8e-3 -- ‡ [34] 
6 Factor IXa ATIII 2.6e-3 -- ‡ [34] 
7 Factor Xa TFPI 16 3.3e-4 [5] 
8 TF-VIIa TFPI-Xa 10 1.1e-3 [5] 
† ka assumed to be at the diffusional limit; kd calculated from equilibrium constant, Kd. 
‡ Irreversible binding reaction. 
 
 
Inhibitory reactions.  Thrombin activates protein C when bound to TM, and the 
thrombin-TM complex is considered the only source for protein C activation.  Factor Xa-
mediated activation of protein C has not been confirmed and, therefore, is not 
considered [35, 36].  Thrombin's ability to participate in procoagulant reactions is 
eliminated once bound to TM.  Irreversible inactivation of factors Va and VIIIa by APC 
follows Michaelis-Menten kinetics.  The cofactor activity of protein S was indirectly 
accounted for through the choice of kinetic parameters for APC-mediated inactivation of 
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factor Va and VIIIa which were measured in the presence of physiologic concentrations 
of protein S [25].  Inactivation of factors Va and VIIIa is assumed to occur at equal rates, 
though factor Va inactivation has been reported to be up to 6x faster than VIIIa 
inactivation [30].  Factors IXa and Xa protect their respective cofactors VIIIa and Va from 
inactivation by APC when associated [25, 37].  PC and APC are assumed to have 
similar diffusion coefficients for computational simplicity.  Antithrombin III irreversibly 
removes factors IXa, Xa, and thrombin by a bimolecular binding reaction.  Acceleration 
of ATIII activity by surface glycosaminoglycans is not considered.  Tissue factor pathway 
inhibitor acts in a two-step process.  TFPI binds reversibly to factor Xa in the fluid phase, 
followed by reversible TFPI/Xa association with surface bound TF/VIIa [5].  Only plasma 
TFPI is considered.  Inducible TFPI from cellular sources, specifically platelets and 
endothelial cells, are not included.   
Flow Regime.  Simulations were conducted assuming a steady, non-pulsatile, 
fully developed parabolic flow profile.  In select instances, analyses were performed for a 
range of shear rates between 100 and 1500 s-1.  However, in most cases, comparisons 
were conducted at simulated arterial (500 s-1) and venous (50 s-1) flow regimes. 
 
3.3.3. Model implementation 
Notation.  Model reactions and corresponding rate constants are summarized in 
Table 3.1.  Postscripts of model parameters correspond to the reaction number (e.g., 
kcat2 is the turnover number for the second reaction, conversion of prothrombin to 
thrombin by Va/Xa).  Fluid phase concentrations are denoted by the letter c followed by 
the numerical species (e.g., c2 refers to the concentration of prothrombin; c5a refers to 
the concentration of Va).  Surface-bound species, defined only at y=0, are additionally 
denoted by the addition of a postscript s (e.g., cTF7as refers to the surface concentration 
of TF/VIIa).   
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Equations.  The full set of partial differential equations and boundary conditions 
can be found in Supplementary Material.  Model equations were non-dimensionalized 
and geometrically scaled to moderate the range of parameter values and to reduce 
mesh size.  All fluid phase species are defined by a conservation equation (Eq. 3.3), 
which contains the rate of accumulation and convective term on the left hand side and 
the diffusive term and fluid-phase reaction rate on the right hand side.  Concentration is 
a function of time and two-dimensional space.  Surface-phase reaction rates appear as a 
flux condition in the boundary conditions.  As an example, the governing equations for 
thrombin (IIa) are presented as follows:   
 3.3 
  3.4 
 3.5 
  3.6 
where ts is a time-scaling coefficient, Pe is a modified Peclet number,  is an 
anisotropic scaling coefficient; c2, c2a, and cAT3 are the concentrations of prothrombin, 
thrombin, and antithrombin III, respectively, c5a10as and cTTMs are the surface 
concentrations of prothrombinase and thrombin-TM, respectively, (TMtotal - cTTMs) is the 
concentration of free TM; R2a is the rate of production of thrombin in the solution phase, 
D2a is the diffusivity of thrombin; kcat2 and Km2 are the turnover number and Michaelis 
constant, respectively, for the conversion of prothrombin to thrombin by prothrombinase 
(Va/Xa), ka3 and kd3 are the association and dissociation constants, respectively for 
thrombin-TM, and ka5 is the irreversible association constant for thrombin-ATIII.   
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The normal flux of factor IIa (c2a) from surface-bound TF is equal to the rate of 
prothrombinase (c5a10as)-catalyzed conversion from factor II (c2) (Eq. 3.4).  The reaction 
is expressed as a Michaelis-Menten rate law governed by the turnover number, kcat2, and 
the Michaelis constant, Km2.  In the vicinity of surface-bound TM, an additional term on 
the right hand side of the flux condition describes the removal of thrombin upon 
bimolecular association with free TM (term beginning with ka3) and the release of 
thrombin back upon dissociation (term beginning with kd3) (Eq. 3.5).  Association and 
dissociation reaction rates are described by second- and first-order rate laws, 
respectively.  The fluid phase reaction rate, R2a, reflects the depletion of thrombin upon 
irreversible binding to ATIII, again defined by a second-order rate law (Eq. 3.6).   
Computer implementation.  The finite element model was implemented in 
COMSOL Multiphysics 3.4 (COMSOL, Inc., Burlington, MA) on a 64-bit Windows 
workstation.  The automatically generated mesh contained approximately 2100 
triangular elements, with finer resolution over the reactive boundaries and intersection 
points.   Soluble species were defined by a convection-diffusion application mode.  
Surface-bound enzymatic complex formation was specified by a weak form (boundary) 
application mode.  Time dependent simulations were solved using a direct parallel 
solver.  Simulations were run to 60 min.  Post-processing was performed in both 
COMSOL and MATLAB (MathWorks, Inc., Natick, MA).   
 
3.3.4. System parameters describing surface-induced thrombin generation over 
spatially discrete regions of TF and TM 
Simulations provide transient concentration profiles in two dimensions for each of 
the 21 computationally-defined species (16 fluid-phase, 5 surface-bound).  System 
parameters were defined to describe the behavior of the initiating TF region and to 
quantify the effectiveness of the TM-expressing downstream region to modulate the 
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thrombin response.  Peak thrombin concentration and flow simulated thrombin 
generation (FSTG) were chosen to evaluate the threshold-like response of the model 
system.  Peak thrombin concentration was defined as the maximum level of thrombin 
attained at any point in the computational space.  FSTG is derived from a consideration 
of the total thrombin generated over the downstream region at y=0 during the course of 
a 60-min simulation, thus acting as a global variable incorporating both spatial and 
temporal information.  The downstream average was chosen as an indication of the 
effectiveness of downstream TM to modulate thrombin production initiated by the 
upstream TF region.  One-hour was chosen as the default simulation time to ensure that 
all phases of coagulation, e.g. initiation and propagation, were included in the analysis 
for all runs.  In other words, the simulation time exceeded the timecourse of the least 
thrombogenic simulation conditions.  A cutoff >10nM FSTG was defined as the „above-
threshold‟ criteria.  Lag time characterizes the initiation phase of the coagulation 
cascade and was defined as the time-intercept of the linear slope that defined the onset 
of the maximum rate of thrombin generation.  Finally, unique to our spatial model, an 
effective prothrombotic zone (EPZ) defined the extent to which thrombin propagated 
away from the site of surface-bound TF, in both axial and radial directions, by delineating 
a region wherein at any point within the space the thrombin concentration was within 
95% of the peak level.  The dimensions of this effective prothrombotic zone, the 
effective prothrombotic length (EPL) and the effective prothrombotic height (EPH) 
were determined as the x-intercept and maximum y-coordinate of the delineating contour 
line, respectively.  It should be noted, therefore, that the effective prothrombotic length 






3.3.5. Modeling tandem lesions 
Additionally, we explored the behavior of systems containing multiple spatially 
distinct sites of surface-bound TF.  The reactive boundary is divided into three spatially 
distinct sites of TF with intervening regions that present surface-bound TM (Figure 3.2B).  
TF length and density were 200 µm and 9 fmol/cm2, respectively.  These TF conditions 
represent lengths and concentrations previously found to be just below the activation 
threshold when adjacent to transport-limited levels of TM (1000 fmol/cm2).  TF lengths 
shorter than the previous section were chosen in order to achieve a wider range of 
effective prothrombotic lengths that would fit within a manageable total chamber length.  
The total length of the system of interest was 3 cm, unless otherwise noted.  A TF 
interval was defined as the distance between the upstream ends of two adjacent sites of 
TF.  Regional flow-simulated thrombin generation (rFSTG) was derived from a 
consideration of the total thrombin generated over the downstream interval regions 
during the course of a 60-min simulation.  An rFSTG>10nM was similarly defined as the 
threshold criteria for characterizing a segment as „above-threshold‟.  Model equations 
governing flow and reaction kinetics remained unchanged.  Similar mesh and solver 








Figure 3.1.  Coagulation reaction network described in the computational model.  
Dotted lines indicate surface-associated complexes.  (A) Procoagulant reactions with 
short- and long-range positive feedback loops (green arrows).  Coagulation is initiated by 
extrinsic pathway (TF-VIIa) activation of FX.  Formation of intrinsic tenase (IXa-VIIa) 
amplifies thrombin generation.  Note that fibrinogen cleavage is not included in the 
model, but is shown for illustrative purposes only.  (B) Anticoagulant mechanisms.  ATIII 
binds irreversibly to FIXa, FXa, and thrombin.  TFPI acts in a two-step mechanism, first 
binding to FXa, followed by formation of the quaternary TFPI-Xa-TF-VIIa complex.  The 









Figure 3.2.  Formulation of a spatially heterogeneous model of surface-induced 
thrombin generation in a flow field.  Blood flow carries proteins into the flow field at 
constant inlet concentrations.  Diffusion transports coagulation factors to the lower 
reactive surface, where reaction kinetics define flux boundary conditions.  Convective 
flux removes soluble species at the outlet.  The upper boundary is inert. (A) Initial 
geometric conditions include a 10 mm entrance region, 2 mm TF region, and a 34 mm 
TM region.  FSTG is defined as the integral of the downstream thrombin surface 
concentration over the 60-min simulation time, normalized by time and length. (B) In the 
tandem model, overall chamber length is fixed at 3 cm.  Three TF regions of length 200 
µm each are spaced at fixed intervals (10 mm in this illustration) with intervening TM 
regions. rFSTG is defined as the integral of the thrombin surface concentration over the 





The degree to which the computational model recapitulated established 
experimental observations was determined for both normal and pathologic systems of 
hemostasis.  The relationship of thrombin generation to increasing surface 
concentrations of TF was initially benchmarked in the absence of TM.  This was followed 
by analysis of APC generation in response to increasing concentrations of surface 
bound TM. Subsequently, the existence of an 'all-or-none‟ threshold effect in a regulated 
coagulation system was defined with respect to the dimensions of the TF region, surface 
densities of TF and TM, and wall shear rate. The capacity of hemophilia A (factor VIII 
deficiency) and B (factor IX deficiency) to modulate the density of surface bound TF 
needed to exceed the threshold for thrombin generation was examined.    Appropriate 
model behavior was further confirmed by examining the time course of a prothrombotic 
system, which is characteristically defined by initiation and amplification phases.  The 
prothrombotic response was compared to a thrombin response, which remained 
suppressed by inhibitory mechanisms.  Significantly, we demonstrate that an effective 
prothrombotic zone may be defined that extends well beyond the dimensions of surface-
bound TF.  The size of this zone is dependent not only on concentrations of all reactive 
species, but also the site of TF expression, the surface densities of TF and TM, as well 
as the characteristics of the flow field.  Furthermore, in the case of multiple sites of TF, 
the relationship between the magnitude of the effective prothrombotic zones and the 
interval distance between TF sites dictated the net thrombotic response of the system.  
Notably, multiple TF sites, which individually failed to activate the coagulation pathway, 
were shown to interact in an additive manner to yield a prothrombotic system.  
Furthermore, the expression of TM in the regions between sites of TF downregulated the 
thrombin response to subsequent TF sites.   
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3.4.1. Thrombin generation increases with increasing TF surface density up to a 
transport limit 
In response to an upstream site of TF expression, surface-associated enzymatic 
complexes assemble on the non-functionalized downstream surface.  Under conditions 
of arterial (500s-1) flow, increasing TF expression in the absence of TM lead to a linear 
increase in the maximum rate of thrombin generation, a reduction in the lag time to 
achieve a maximum rate of thrombin production, and a concomitant increase in FSTG 
(Figure 3.3A).  Both the lag time and FSTG approached a transport limit at a TF density 
of ~1 fmol/cm2.  Above this surface concentration of TF, full activation of the coagulation 
cascade resulted in approximately 86% peak substrate conversion (~1200 nM thrombin 
generated / 1400 nM inlet prothrombin).  At or below a TF concentration of 0.2 fmol/cm2, 
full activation of the coagulation cascade was not observed, which reflects the capacity 
of flow to suppress thrombin production by active removal of reactive species, unless, as 
detailed below, the dimension of the TF region are increased.  Similar effects were 
observed at 50s-1, although the transport limit was defined by a significantly lower TF 
surface concentration (data not shown).   
 
3.4.2. APC generation increases with increasing TM surface density up to a 
transport limit 
Activated protein C (APC) concentrations as a function of TM surface density 
were determined in response to a fixed TF stimulus ([TF] 0.8 fmol/cm2).  Under arterial  
(500 s-1) conditions, APC concentration increased with increasing TM concentration up 
to ~500 fmol/cm2.  At higher levels of TM, the reaction became substrate-limited with 
94.8 and 97.1% peak substrate conversion within the local environment of the TM 
surface at TM concentrations of 500 and 1000 fmol/cm2, respectively (Figure 3.3B).  
Under transport-limited conditions, the reaction rate for APC production exceeded the 
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rate of substrate delivery and product removal.  The transport-limited TM concentration 
is in general agreement with experimental studies previously conducted in our laboratory 
[38]. 
 
3.4.3. The model system exhibits threshold responses to tissue factor, 
thrombomodulin, and wall shear rate 
Characteristically, during the initiation phase of coagulation, very low levels of 
thrombin are produced.  During this phase, inhibitors may dampen the thrombin 
response and prevent amplification and full activation of the coagulation cascade; this is 
considered a 'sub-threshold' thrombin response.  However, when the capacity of these 
inhibitors is overwhelmed by the magnitude of the thrombogenic stimulus, thrombin 
levels cross an activation threshold and rapid amplification of thrombin generation 
occurs.  This threshold effect may be defined with respect to a number of variables (e.g. 
blood flow, fluid- and surface-phase levels of procoagulant factors and inhibitors, kinetic 
variables), and thus an infinite set of threshold-defining permutations exist beyond which 
thrombin is produced in an almost instantaneous manner.  Using our computational 
model, we conducted parametric studies which would not have been experimentally 
efficient.  With respect to our system parameters, peak thrombin concentration reflected 
the 'all-or-none' behavior of thrombin generation and easily differentiated between sub-
threshold and fully activated systems.  Likewise, by setting a cutoff of 10nM for FSTG, 
notably the concentration reported to induce platelet activation [39], systems were 
reliably categorized into sub- and above-threshold groups.  By incorporating both spatial 
and temporal information, FSTG was additionally a sensitive parameter that further 
enabled stratification of prothrombotic states.   
We examined the relationship between the length of the TF region and thrombin 
production while maintaining TF and TM surface densities at or near transport-limited 
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levels of 1 and 1000 fmol/cm2, respectively.  At a shear rate of 500 s-1, peak thrombin 
concentration and FSTG fell below the activation threshold of 10 nM, if the TF site was 
less than 1.6 mm in length (Figure 3.4A and B).  With further lengthening of the TF 
region, peak thrombin concentration and FSTG increased sharply and peak thrombin 
approached 1200 nM, consistent with full activation of the coagulation cascade.   
A similar threshold effect was observed in relation to TF surface concentration.  
At venous (50 s-1) and arterial (500 s-1) shear rates, TM (1000 fmol/cm2) inhibited 
thrombin production at TF concentrations below 0.03 and 0.8 fmol/cm2, respectively.  
However, at TF densities that exceeded these concentrations, peak thrombin 
concentration reached substrate-limited levels (~1200 nM) and FSTG exceeded the 10 
nM activation definition (Figure 3.4C and D, venous data not shown).   Threshold-type 
behavior was also observed in relation to TM surface concentration (Figure 3.4E and F).  
Minimum TM surface densities required to limit thrombin propagation were 1.4 and 60 
fmol/cm2 for TF concentrations of 0.03 and 0.8 fmol/cm2 under venous and arterial shear 
rates, respectively.  As would be anticipated, the magnitude of flow had a pronounced 
effect on the threshold for thrombin production, as well.  Assuming a TF site of 2 mm in 
length and TF and TM concentrations of 1 and 1000 fmol/cm2, respectively, threshold 
activation was suppressed at shear rates above 750 s-1 (Figure 3.4G and H). 
 
3.4.4. Hemophilia A & B increase required levels of tissue factor and reduce the 
rate of thrombin formation 
Model simulations confirm that threshold requirements for activation of the 
coagulation cascade are increased for moderate hemophilia A and B when compared to 
a normal hemostatic system.  Specifically, the concentration of surface-bound TF 
required to surpass the threshold for thrombin production were approximately two-fold 
higher under arterial and venous conditions.  Moreover, the more gradual transition to 
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full amplification of the coagulation cascade, as evident by the slower rise of peak 
thrombin production in response to the concentration of surface-bound TF, is consistent 
with a dampened positive feedback system (Figure 3.5A and B).  Similarly, the 
hemophilias were associated with a decrease in the rate of thrombin generation and a 
lower FSTG (Figure 3.5C and D).  Notably, despite increasing the concentration of TF to 
compensate for the hemophilic state, such that the peak thrombin concentration is 
similar to that attained under normal hemostatic conditions, a normalized rate of 
thrombin production was not achieved.  Under arterial (500 s-1) flow, the maximum rate 
of thrombin generation was 48.8 nM/min under normal hemostatic conditions ([TF] 1 
fmol/cm2), while half that (14.2 nM/min) for hemophilia A, despite doubling the surface 
density of TF to 2 fmol/cm2 to afford similar peak thrombin responses.  Likewise at low 
shear (50 s-1), the maximum rate of thrombin generation was 26.3 nM/min under normal 
hemostatic conditions ([TF] 0.04 fmol/cm2), but less than one-half of that (10.9 nM/min) 
for hemophilia A conditions even when expressed tissue factor was increased to 0.08 
fmol/cm2 to yield similar maximum levels of thrombin. Indeed, experimental studies have 
noted that hemophilia A and B are associated with decreased rates of thrombin 
generation [40].   
 
3.4.5. The effectiveness of APC to inhibit the onset of the amplification phase of 
coagulation is determined within the first 3-5 min of the 
initiation phase 
The time course of thrombin, factor Va, and APC production was examined for 
systems residing at an activation interface.  Under conditions in which an activation 
threshold was exceeded (e.g., TF 0.9 fmol/cm2, TM 1000 fmol/cm2, 500 s-1), modulation 
of Va and thrombin production by APC occurred within the first 3-5 min, but after an 
initiation period of 37 min, thrombin concentration rose rapidly and plateaued at a 
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substrate-limited level of 1180 nM (Figure 3.6A).  In contrast, below an activation 
threshold, (e.g., TF 0.8 fmol/cm2, TM 1000 fmol/cm2, 500 s-1), Va decreased in response 
to increases in APC, restricting thrombin to very low levels.  The effectiveness of factor 
Va suppression by APC is determined within the first few minutes, with Va 
concentrations reaching steady state by approximately 20 min for the sub-threshold case 
(Figure 3.6B).  These results are similar to pseudo-one compartment models run by 
Kuharsky et al. under conditions of high and low TF density [9].   
 
3.4.6. Extrinsic tenase governs initiation of coagulation, while intrinsic tenase 
governs amplification 
The intrinsic and extrinsic pathways converge on the common pathway to 
generate factor X and thrombin.  The time courses of intrinsic tenase (IXa/ VIIIa), 
extrinsic tenase (TF/VIIa), and prothrombinase (Xa/Va) was evaluated under arterial flow 
conditions (Figure 3.6C and D).  Extrinsic tenase is produced rapidly as flow and 
diffusion transport circulating VIIa to surface-bound TF.  As factors IX and VIII are 
activated by TF/VIIa and thrombin, respectively, subsequent formation of intrinsic tenase 
is observed.  Overall prothrombinase assembly, and subsequent thrombin production, 
follows the time course established by intrinsic tenase.  These computational results are 
consistent with the role of the extrinsic pathway in initiation and the importance of the 
intrinsic pathway in amplification of coagulation [3, 41, 42].   
 
3.4.7. Tissue factor, thrombomodulin, and shear rate dictate the dimensions of an 
effective prothrombotic zone that extends beyond the 
initiating site of thrombin generation 
These studies emphasize the existence of a spatially defined zone of thrombin 
that may extend well beyond the site of TF expression. Under arterial flow conditions 
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(500 s-1), the threshold length for surface bound TF at 1 fmol/cm2, above which explosive 
thrombin production is observed, was previously determined to be 1.6 mm.  Although 
activation of coagulation at this dimension is relatively limited, this case conveniently 
illustrates the presence of an effective prothrombotic length (EPL) that is characterized 
by thrombin propagation in space.  This phenomenon holds true whether or not a system 
exceed an activation threshold.  As shown in Figure 3.7A, the relationship between a 
spatially discrete site of TF expression and the effective prothrombotic length is non-
linear.  For example, increasing the size of the TF region by 60% (from 1 mm to 1.6 mm) 
leads to a 640% increase in the EPL (3.06 versus 19.6 mm).   
The influence of the flow regime on the dimensions of the effective prothrombotic 
zone was investigated at shear rates ranging from 500 to 2000 s-1.  It might be 
anticipated that higher flow rates would promote downstream propagation of thrombin.  
However, increasing shear rate decreased the effective prothrombotic zone, due to 
enhanced removal of activated clotting factors and greater APC generation attributed to 
increased transport of thrombin and protein C to TM.  Propagation of the effective 
prothrombotic zone in both parallel and perpendicular to the direction of flow was 
reduced at higher shear rates (Figure 3.7B).  In particular, at the chamber outlet (x=3.6 
cm), the height of the effective prothrombotic zone increased linearly from 11.3% to 
15.3% of the total chamber height, and the length increased non-linearly from 0.49 to 
0.95 cm for shear rates of 2000 and 750s-1, respectively.   
Increasing TF and TM surface concentration lead to a respective increase or 
decrease in the dimensions of the prothrombotic zone.  Specifically, the length of the 
effective prothrombotic zone increased exponentially with TF density (Figure 3.7C), 
while decreasing in response to TM (Figure 3.7D).  The effective prothrombotic length 
was linearly related to peak APC concentration.  It is noteworthy that similar EPZ 
dimensions may arise from widely varying sized sites of TF expression, TF and TM 
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concentrations, and shear rate.  Steady state surface plots of thrombin concentration for 
decreasing concentrations of surface TM are shown in Figure 3.8.  Under conditions that 
did not exceed the activation threshold (Panel B), the effective prothrombotic zone 
remained near the site of TF expression.  For conditions in which an activation threshold 
was exceeded (Panels C and D), the effective prothrombotic zone encompassed and 
extended beyond the entire downstream region.   
 
3.4.8. Thrombomodulin expression within the intervening regions dictates the 
suppressive interactions that occur between sequential TF 
sites 
Multiple TF sites acted cooperatively to promote or suppress thrombin 
generation, dependent, in part, on the concentration of surface-bound TM within 
intervening regions.  In Figure 3.9, mean thrombin concentrations generated in three 
regions located between sequential sites of TF were compared as a function of TM 
surface densities ranging from 40 to 1000 fmol/cm2.  TF length and concentration were 
fixed at 200 µm and 9 fmol/cm2, respectively.  The interval distance between TF sites 
was 1 cm.  At low levels of TM, thrombin generated from the first TF region enhanced 
thrombin production at downstream TF sites by driving positive feedback loops of the 
coagulation cascade.  At intermediate levels of TM expression, thrombin generated by 
the upstream site additionally served to activate protein C, thus counteracting thrombin 
propagation to some degree.  Significantly, at high surface densities of TM, the extent of 
thrombin-mediated APC generation was great enough to suppress thrombin production 
by downstream sites of TF.  The degree of suppression between TF sites was 
proportional to TM surface concentration and was more pronounced between the first 
and second regions than between the second and third TF sites (56 and 8% decrease in 
mean thrombin, respectively for [TM] 500 fmol/cm2 and 83 and 28% decrease, 
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respectively for [TM] 1000 fmol/cm2).  Because thrombin regulates its own generation 
through the activation of protein C, the dampened suppressive effects between the 
second and third TF sites can be accounted for by the reduced levels of thrombin 
generated by the second TF site.  Representative surface plots of thrombin 
concentration for additive, intermediate, and suppressive interactions that occur between 
sequential sites of TF are shown in Figure 3.9.  We observed that extent to which 
sequential regions of TF and TM acted to inhibit or promote thrombin generation was 
dictated by the degree to which tandem effective prothrombotic zones overlapped. 
 
3.4.9. The sequential interaction of effective prothrombotic zones produced by 
tandem sites results in enhancement of the overall 
thrombotic response  
Figure 3.10 depicts mean thrombin concentration in three regions located 
downstream to each TF site (TFlength 200 µm, [TF] 9 fmol/cm
2) for interval distances of 
0.5, 1, and 2 cm.  The overlap of the effective prothrombotic zones of high density TF 
sites spaced 1 cm apart is illustrated in Figure 3.10.  Encroachment of the effective 
prothrombotic zones of upstream TF sites over downstream sites promotes thrombin 
generation over the downstream sites by contributing to positive feedback loops of the 
coagulation cascade.  In Figure 3.10A, the length of the effective prothrombotic zone (>3 
cm) was much greater than the interval distance, resulting in considerable overlap of 
effective prothrombotic zones and cumulative thrombin levels in downstream regions 
which greatly exceeded the 10 nM activation threshold.  The intensity of the additive 
effects increased as the interval distance was decreased.  Moderate overlap of the EPZs 
(length ~1.3 cm) resulted in some additive propagation of thrombin generation to 
downstream sites (Figure 3.10B).  However, in the presence of higher TM surface 
concentrations, thrombin also functioned to activate protein C, leading to suppression of 
 51 
thrombin generation.  The net effect was an apparent lack of, or minimal, interaction 
between TF sites.  Prothrombotic interactions played a larger role when the TF sites 
were more closely positioned.  Conversely, when the interval distance was increased 
such that the EPZ no longer overlapped, suppressive effects begin to dominate.  These 
suppressive effects were particularly pronounced at a TM surface concentration of 1000 
fmol/cm2 with limited overlap of effective prothrombotic zones.  The capacity of tandem 
sites to inhibit thrombin generation is attenuated by prothrombotic interactions as the 
distance between sites approach the boundaries of the effective prothrombotic zone 
(Figure 3.10C).  For example, at interval distances of 2, 1, and 0.5 cm, mean thrombin 
concentration between the first and second sites of TF expression decreased by 86, 83, 










Figure 3.3.  Characterization of transport-limited regimes under arterial flow (500s-
1) (A) Mean downstream thrombin generated by a localized TF region of length 2 mm in 
the absence of TM expression in the downstream region. (B) Simulated peak APC 
generation as a function of TM surface density in response to a fixed TF stimulus located 











Figure 3.4.  Threshold response of thrombin to TF site length, TF surface density, 
and TM surface density under simulated arterial flow (500 s-1).  (A, B) Peak thrombin 
concentration and FSTG as functions of the length of the site of TF expression at a wall 
shear rate of 500 s-1.  TF and TM surface densities were 1 and 1000 fmol/cm2, 
respectively.  (C, D) Peak thrombin concentration and FSTG as functions of TF surface 
density.  TF and TM lengths were 2 and 34 mm, respectively.  TM surface concentration 
was fixed at 1000 fmol/cm2.  (E, F) Peak thrombin concentration and FSTG as functions 
of TM surface density.  TF surface concentration was fixed at 0.8 fmol/cm2.  (G, H) Peak 
thrombin concentration and FSTG as functions of wall shear rate.  TF and TM lengths 
were 2 and 34 mm, respectively.  TF and TM surface densities were 1 and 1000 
fmol/cm2, respectively.  Simulations were run to 60-min.  Activation of clotting is defined 







Figure 3.5. Threshold response of thrombin generation to TF surface density for 
normal physiologic and hemophiliac conditions.  Peak thrombin (A, B) and FSTG 
(C, D), during the course of a 60-min flow period at wall shear rates of (A, C) 500 s-1 and 
(B, D) 50 s-1.  [TM] 1000 fmol/cm2.  Moderate hemophilias A and B (5% normal FVIII & 
FIX, respectively) increase the TF concentration required to exceed the activation 









Figure 3.6.  Time course for coagulation systems that lie above or below a 
prothrombotic activation threshold.  Throbmin, APC, and factor Va concentrations at 
the TF-TM intersection (x=0.2 cm) at 500 s-1 for systems that exceeded (TF 0.9 
fmol/cm2, TM 1000 fmol/cm2) (A) or resided below (TF 0.8 fmol/cm2, TM 1000 fmol/cm2) 
(B) an activation threshold.  Total upstream extrinsic and intrinsic tenase and 
prothrombinase concentrations at 500 s-1 for systems that exceeded (TF 0.9 fmol/cm2, 
TM 1000 fmol/cm2) (C) or resided below (TF 0.8 fmol/cm2, TM 1000 fmol/cm2) (D) an 






Figure 3.7.  Factors influencing the length of the EPZ.  Relationship of effective 
prothrombotic length to (A) TF length, (B) wall shear rate, (C) TF density, and (D) TM 
density.  Effective prothrombotic height, as a percentage of total chamber height, is 
plotted in panel (B).  For panels (A-C), TF length was 2 mm, wall shear rate was 500 s-1, 
[TF] 1 fmol/cm2, and [TM] was 1000 fmol/cm2 when fixed.  (D), [TF] 0.8 fmol/cm2 




Figure 3.8.  Effective prothrombotic zone and its dependence on TM surface 
concentration.  Thrombin generation is initiated at a wall shear rate 500 s-1 in response 
to a region 2 mm in length expressing TF at a density of 0.8 fmol/cm2.  Simulations are 
run to 60-minutes.  (A) EPZ as a function of TM surface density (1000, 500, 100, and 80 
fmol/cm2).  Steady state thrombin concentration profiles for downstream TM densities of 
(B) 1000, (C) 100, and (D) 10 fmol/cm2.  The EPZ is delineated by a contour line wherein 
at any point within the space the thrombin concentration was within 95% of the peak 
















Figure 3.9.  Additive, intermediate, and suppressive interactions between tandem 
prothrombotic sites.  (A) rFSTG as a function of intervening TM surface density (40-
1000 fmol/cm2) under simulated arterial conditions (500 s-1) over three sequential sites of 
TF (TFlength 200 µm, [TF] 9 fmol/cm
2).  From left to right, each bar represents rFSTG for 
the regions downstream of each site of surface-bound TF.  (B-D) EPZ, previously 
calculated from a simulation of a single site of TF, is overlaid on the surface plot to 
illustrate the overlap of EPZ between sequential TF sites.  Panel (B) is representative of 
additive effects at low surface densities of TM (40 fmol/cm2).  Panel (C) is representative 
of the net effect of both additive and suppressive interactions between TF sites at 
intermediate surface concentrations of TM (100 fmol/cm2).  Panel (D) is representative of 
suppressive interactions between TF sites at high surface concentrations of TM (1000 
fmol/cm2).  Simulations were run to 60 min.  However, concentration profiles shown here 


















Figure 3.10.  Effect of TF interval on additive and suppressive interactions 
between tandem TF sites.  From left to right, each bar represents rFSTG for the 
regions downstream of each site of surface-bound TF during the course of a 60-min flow 
period at a wall shear rate of 500 s-1.  TFlength 200 µm, [TF] 9 fmol/cm
2.  Varied EPL 






3.5.1. Computational modeling of blood coagulation 
Several models restrict their analysis to reaction kinetics of all or part of the 
intrinsic, extrinsic, and common pathways, neglecting the role of blood flow.  Nesheim et 
al. [43] explored the properties of prothrombinase assembly and activity within an 
interface shell surrounding phospholipid vesicles in solution in a steady-state, two-phase 
model.  Willems et al. [44] studied a dynamic model of thrombin generation in plasma 
describing 14 pro- and anti-coagulant reactions, including inhibition of coagulation by 
activated protein C, antithrombin III, and exogenous hirudin.  The stimulus was a 
transient pulse of factor Xa, and a threshold response to this stimulus was reported that 
was dependent on ATIII inactivation of thrombin and factor Xa.  Jones and Mann [45] 
developed a more complex model of the dynamics of coagulation, which included the 
activation of factors IX, X, V, VIII, and thrombin, assembly of the phospholipid-
associated enzyme complexes, intrinsic tenase (IXa/VIIIa) and prothrombinase (Xa/Va), 
and initiation of thrombin generation by TF/VIIa.  This model was subsequently extended 
to include a number of additional substrate interactions and positive feedback 
mechanisms, and significantly, incorporated the coagulation inhibitors, tissue factor 
pathway inhibitor (TFPI) and antithrombin III (ATIII), resulting in a model system 
describing the fate of 34 species [41].  Jesty and colleagues [46-48] considered, both 
analytically and numerically, the threshold behavior that resulted from representative 
systems ranging from an auto-activating zymogen-enzyme pair, to systems of two or 
four zymogen-enzyme pairs with multiple positive feedback mechanisms subject to 
irreversible, first-order inactivation.  In the presence of coagulation inhibitors, all systems 
exhibited threshold behavior, which was modulated by changes in initial concentrations 
of active enzymes, enzyme kinetics, the presence of multiple positive feedback loops, 
membrane patch size, and in later models, flow [46-48].  Similarly, Bungay et al. [49, 50] 
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demonstrated the dependence of a threshold response on the availability of phospholipid 
surfaces.   
Computational models that have incorporated the effects of blood flow have 
commonly used a simple compartmental modeling approach, which divides the vascular 
space into two compartments, a boundary volume and a bulk volume.  Additionally, 
pseudo-one compartment models assume that changes within the bulk phase are 
negligible, thereby reducing the problem to a system of ordinary differential equations 
[51].  Baldwin and Basmadjian [8] published a limited model of six reactions, including 
two positive feedback reactions and two inhibitory reactions, of the common pathway of 
coagulation triggered by exogenous factor IXa under flow.  The major finding of the 
study was the predicted effect of increased mass transport to enhance thrombin 
generation by decreasing the induction time up to a critical mass transfer rate, beyond 
which transport significantly decreased peak thrombin levels, thereby reducing overall 
thrombin production.  Kuharsky and Fogelson [9] formulated a more comprehensive, 
pseudo-one compartment model of tissue factor-initiated coagulation under flow, which 
included the description of 59 distinct fluid- and surface-bound species. In the process, 
the threshold response of thrombin generation was related to the availability of 
membrane binding sites.  In contrast to the Baldwin-Basmadjian model, which defined 
the mass transfer coefficient in terms of the rate of transport to the vessel surface, the 
Kuharsky-Fogelson model defined the mass transfer coefficient as a rate of transport 
into the boundary volume, thus eliminating the dependence of kinetic parameters on 
transport parameters.  This model was subsequently extended by Fogelson and Tania 
[52] to include protein C and TFPI pathways.  While the Fogelson models incorporated 
the essential phenomena of flow and surface reactivity, their indirect method relied 
heavily on the assumption of well-mixed compartments and therefore is limited at low 
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shear rates, for large surfaces, and physiologic relevance of a homogeneous surface 
presentation.  
Ataullakhanov and colleagues [10, 11] developed mathematical models to 
describe the spatial dynamics of clot formation initiated by a monolayer of TF-expressing 
cells in the direction perpendicular to the vessel wall.  Extrinsic, intrinsic, and protein C 
pathways were represented by 27 partial differential equations.  Major findings include 
the roles of these specific coagulation pathways in the initiation, amplification, and 
termination phases of coagulation.  It was observed that coagulation near the activating 
surface was determined by TF/VIIa catalyzed factor Xa production, while clot formation 
away from the reactive wall was dependent on intrinsic tenase (IXa/VIIIa) activity.  These 
studies provide an interesting analysis of the roles of specific factors in relation to space 
due to diffusive effects, but neglect the essential role of blood flow in the transport 
analysis.  Additionally, the spatial dynamics of clot localization by thrombomodulin would 
likely be affected by restricting the inhibitor to its physiologic site on the vessel surface.  
Ismagilov et al. studied the threshold response of coagulation to various spatial 
parameters in microfluidic systems of TF-patterned phospholipid surfaces [12].  
Numerically, initiation of a representative autocatalytic system by different sized and 
shaped patches was simulated using a finite element model, which defined three 
reactions and diffusion.  The reaction 'modules' represented the kinetics of: 1) activation 
by the stimulus patch, corresponding to TF-mediated initiation of coagulation, 2) 
autocatalytic production of the activator in solution, representing the positive feedback 
mechanisms of coagulation, and 3) linear consumption of the enzyme product in 
solution.  A threshold response to the size and shape of the TF patch was empirically 
and numerically shown to follow a simple scaling relationship based on the ratio of the 
rate of diffusion off the patch to the rate of generation of the activating species [53, 54].  
Runyon et al. [55] described the propagation of clotting from an initiating microchannel 
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into a perpendicularly oriented channel with flowing plasma.  In small microchannels, 
clotting was shown to be inhibited by surface-bound inhibitors, specifically TM, while in 
larger microchannels, the threshold response of clotting was regulated by the shear rate 
in the cross-flowing channel.  The simple numerical experiments served primarily to 
confirm experimental observations, and with the exception of the cross-flow channel, 
convective effects were not considered. 
We have characterized a computational model of coagulation, which integrates 
the effects of reaction kinetics, a simple, yet computationally expandable, flow regime, 
and uniquely heterogeneous surface expression.  Our model simulated threshold effects 
with respect to the length of the TF site, TF and TM surface densities, and wall shear 
rate, and reproduced the classic time course characterized by initiation and amplification 
of thrombin generation.  Furthermore, our TF length threshold was consistent with 
experimental work by Shen and colleagues who measured a TF threshold size of 
approximately 400 µm in a capillary perfusion system under low shear rates (40 s-1) in 
the absence of TM regulation [56].  Interestingly, the threshold TF length in this study at 
transport-limited levels of TF and TM was found to be within the length range of ruptured 
plaques associated with acute thrombotic occlusion [20].  With respect to TF density, we 
computed thresholds of 0.03 and 0.8 fmol/cm2 for wall shear rates of 50 and 500 s-1, 
respectively.  Using patterned microarrays, Okorie et al. determined critical TF 
concentrations of 0.6, 1.4, and 1.7 fmol/cm2 for wall shear rates of 100, 500, and 1000 s-
1, respectively [57].  Computationally, Kuharsky and Fogelson predicted a TF density 
threshold of approximately 3 fmol/cm2 at 500 s-1 [9].  It has been estimated using ex vivo 
carotid plaque scraping that the average phospholipid membrane-associated TF 
underlying atherosclerotic plaques is 33 pg TF/cm2, or 1 fmol/cm2 [58].  The principle of 
a TF threshold is significant since it is unlikely that the vasculature is completely without 
defect.  An understanding of the regulation of blood coagulation requires consideration 
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not only of antithrombotic biochemical pathways, but also consideration of coagulation 
thresholds.  As we have demonstrated, these variables may not be studied in isolation; 
for example, wall shear rate has profound effect on TF density threshold. 
In addition to generating complete concentration profiles for each coagulation 
factor and inhibitor, we have defined a global parameter, FSTG, which reflects three key 
qualities of the thrombin response: 1) intensity of response, 2) relative onset of 
amplification, and 3) localization of the thrombin foci near to the upstream injury area.  
Sub-threshold systems are characterized by FSTG <10nM, while those systems that 
cause full activation of the coagulation cascade fall along a continuous scale >10nM 
FSTG.  The choice of a consistent one-hour simulation time ensured inclusion of early 
and late phases of coagulation.  While there is some post-processing loss of information 
due to averaging, it is notable that the results of spatially homogeneous models are 
intrinsically averaged.   
Perhaps the most intriguing result of this study was the identification of an 
effective prothrombotic zone (EPZ) that may be significantly larger than the dimensions 
of the spatially discrete site of tissue factor expression in both radial (EPH) and axial 
(EPL) directions, with implications for clot growth leading to arterial or venous 
thrombosis, as well as systemic procoagulant effects leading to further 
hypercoagulability.  The geometric parameters EPL and EPH are therefore measures of 
the vital function of hemostasis to confine thrombus formation to an injury site.  Shen et 
al. reported that spatial propagation of thrombin was limited to a 100-µm distance from a 
discrete patch of TF, under conditions which did not lead to exceeding a threshold for 
thrombin propagation [56].  Significantly, a remarkable increase in the effective 
prothrombotic zone may occur under conditions that lead to a reduction in the surface 
concentration of thrombomodulin. This effect is further enhanced in a low flow regime.  
These results are consistent with those reported by Ataullakhanov and colleagues for 
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experimental and computational studies for a diffusion limited system, in which thrombin 
generation and clot formation were inhibited by solution-phase TM with final clot lengths 
of 0.2-2 mm under diffusive conditions [10, 11].   
 
3.5.2. Simulated hemophilias 
Hemophilias A and B are X-linked genetic deficiencies of factor VIII and IX with 
annual worldwide incidence of 1:5,000 and 1:30,000 male births, respectively. Both 
“severe” (<1% of normal, 50-60% of pts) and “moderate” (<5% of normal, 25-30%) 
hemophilia patients experience spontaneous bleeding into joints and soft tissues and 
excessive bleeding with surgery or trauma.  Recurrent episodes of intra-articular 
hemorrhage and inflammation cause progressive damage to cartilage and bone, leading 
to disabling arthropathy [59].  Factors VIII and IX are components of the enzyme 
complex, intrinsic tenase, which is essential for the rapid rate of thrombin formation 
during the propagation phase of coagulation.  It has been shown that the rapid thrombin 
burst, not simply high concentrations of thrombin, contributes to the formation of a stable 
fibrin plug that is resistant to premature fibrinolysis.  Thus, although initial clot formation 
is often normal in hemophilia patients, the loose fibrin networks formed are easily 
dissolved leading to prolonged bleeding [60, 61].  Consistent with these experimental 
reports, lower maximum rates of thrombin generation were observed in our simulation 
for both hemophilia A and B.  Additionally, we determined that both hemophilic states 
required an increase in TF density for activation of coagulation as compared to a normal 
hemostatic system without these deficiencies.  Of note, the parameter FSTG reflected 
changes in both the peak thrombin concentration and the maximum rate of thrombin 
generation.   
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3.5.3. Atherosclerosis and the importance of interactions between multiple 
lesions 
Despite advances in prevention, patient education, and pharmaceutical 
therapies, atherosclerosis remains a significant source of morbidity and is estimated to 
be responsible for nearly 75% of all cardiovascular-related mortality [62].  
Atherosclerosis is a diffuse disease affecting all vessels and long range communication 
between sites cannot be excluded, particularly in the presence of flow.  Furthermore, 
tandem lesions, or more than one stenosis in series within a single coronary or carotid 
artery, are common occurrences and pose unique hemodynamic challenges [63, 64].   It 
may be concluded from these computational observations, that measurement of lesion 
morphology [65] is not sufficient for determining the vulnerability of coronary 
atherosclerotic plaques and the likelihood of acute coronary syndromes or sudden 
cardiac death.  The number and distance between lesions may be of equal or greater 
importance.  Indeed, it has been suggested that smaller, non-obstructive plaques, could 
be most dangerous simply because they by far outnumber the larger, obstructive 
plaques [66].  Accurate assessment of plaque vulnerability and subsequent 
management of high-risk plaques or 'systems of plaques' through pharmaceutical or 
interventional therapies could greatly diminish morbidity associated with ischemic 
cardiac injury and decrease the incidence of sudden cardiac death [67].   We have 
explored blood coagulation in the setting of multiple spatially discrete regions of tissue 
factor expression.  The existence of an effective prothrombotic length that extends 
significantly beyond the anatomical dimensions of an injury site establishes a foundation 
for procoagulant interactions between the injury sites.  The effective prothrombotic 
length is governed not only by the dimension and concentration of the TF-expressing 
site, but also by flow effects and surrounding TM-protein C pathway regulation.  As a 
consequence, the additive effects of more than one sub-clinical atherosclerotic plaque 
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lesion may result in a clinically relevant thrombotic response.  The major determinant of 
a system‟s overall pro- or anti-thrombotic behavior is the relationship between the 
effective prothrombotic length and the interval distance between lesions.  More 
precisely, the relationship between the effective prothrombotic length and the interval 
distance governs the intensity of additive, prothrombotic interactions.  In contrast, 
suppressive interactions are governed by the surface density of TM within the 
intervening regions.  In our analysis of the effect of the EPL to interval distance ratio, the 
effective prothrombotic length was shortened by increasing TM surface concentration.  
This had the confounding effect of also causing downregulation of thrombin generation 
over downstream TF sites.  The effective prothrombotic length may also be shortened by 
decreasing the surface concentration of TF.   
Acute clinical events including stroke and myocardial infarction (MI) occur upon 
rupture of atherosclerotic plaques.  Exposure of large amounts of tissue factor (TF) to 
the bloodstream from within the necrotic core of plaque lesions is thought to be 
responsible for the hyperthrombotic state of atherosclerotic vessels [68-70].  Campo et 
al. measured factor VII and TF antigen levels for 256 patients admitted for acute MI and 
correlated these levels with increased incidence of death and reinfarction within a 
median follow-up period of 397 days (hazard ratio 2.1 for FVII and 4.1 for TF) [71].  The 
investigators of the AtheroGene study, which included 1669 patients with coronary artery 
disease (CAD) with a median follow-up of 2.3 years, reported a hazard ratio of 2.06 for 
soluble plasma TF levels and cardiovascular death in individuals with acute coronary 
syndrome [72].  Similarly, a 30-year review of the Northwick Park Heart Study (NPHS-1) 
observed a significant association of factor VII with fatal coronary heart disease (RR 
1.58 in men, 1.78 in women); no correlation was found with non-fatal heart disease [73].  
Amiodarone, an anti-arrhythmic agent known to decrease mortality in patients with CAD 
and decreased ejection fraction, has been shown to interfere with tumor necrosis factor 
 69 
(TNF )- and thrombin-induced TF expression in culture human vascular cells as well as 
in a mouse photochemical carotid injury model [74]. 
Interestingly, upstream TF regions promote TM and thrombin-mediated 
generation of the anticoagulant APC that acts to dampen the thrombin response at distal 
sites.  In a study of 335 patients admitted to the emergency department for ST-elevation 
myocardial infarction, decreased APC levels were found to be a prognostic parameter 
for high risk of death with an adjusted odds ratio of 9.4 for an APC cutoff at 65% [75].  In 
a retrospective study comparing patients with severe atherosclerosis and ischemic 
cardiomyopathy to matched controls, Laszik et al. [76] determined a 2.4-fold decrease in 
thrombomodulin staining of endothelial cells of the coronary arteries.  In concordance 
with our findings, it may be inferred that management strategies which support TM 
expression and upregulation should be encouraged in patients found to have more than 
a few coronary plaques, despite the apparent sub-clinical size of individual lesions.  The 
effects of TM surface concentration may also have implications for early autologous vein 
graft failure due to thrombosis.  Immunohistochemical staining and Western blot analysis 
revealed a transient reduction in TM expression of over 95% during the first 2 weeks 
following implantation of autologous vein graft sections in a rabbit model [77].    
 
3.5.4. Model limitations and extensions 
Certainly, any theoretical model is limited in the absence of direct experimental 
validation.  However, experimental studies in a parallel plate flow reactor of TF- and TM-
functionalized membrane-mimetic assemblies yielded predictions of surface densities for 
mass transfer limited regimes which were within reasonable agreement with numerical 
studies.  Direct experimental vaildation is challenging given the obstacles of obtaining 
species concentrations at specific spatial points within the flow field with sufficient 
temporal resolution.  Moreover, the measurement of outlet concentrations becomes 
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irrelevant for systems in which thrombin generation is effectively localized to the 
upstream environment, as extremely minute concentrations, diluted additionally by the 
bulk stream and the collection volume required for assay, would need to be detected.  
Given the available indirect validation and the relatively well-defined nature of the 
coagulation cascade, it is likely that the model provides a close approximation of 
surface-induced thrombin generation under flow conditions.   
Our computational model is not without value in its ability to simulate features of 
the coagulation cascade, namely the rapid 'all-or-none' response of thrombin activation, 
characteristic initiation and amplification phases, and quantitative values within the 
appropriate range of concentrations.  While it may be suggested that any phenomena 
may be mathematically reproduced given 16 diffusion coefficients, 10 inlet 
concentrations, and 36 kinetic parameters, it bears emphasis that the reaction pathways 
and related kinetic parameters are largely well-defined for the coagulation cascade, and 
furthermore, that no parameter fitting was performed for our model system.  Given a 
different set of physiologically relevant parameters, the qualitative trends observed in our 
studies would have remained the same, though quantitative values may have changed 
to some degree.   
A number of simplifying assumptions were made for reasons of computational 
simplicity and feasibility.  First, steady, one-dimensional laminar flow in a two-
dimensional, rectangular flow field was assumed.  This simple, algebraically-defined flow 
profile enabled the effect of wall shear rate to be directly studied, but did not reflect the 
pulsatile flow of the arterial system or turbulent flow patterns often observed at 
bifurcation, or branching points.  It should be noted, however, that the FEM approach 
taken in these studies allows for the possibility of incorporating more complex flow 
geometries and non-steady flows by the addition of the Navier-Stokes equation to solve 
for x- and y- components of flow velocity, or by coupling to other existing computational 
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fluid dynamics (CFD) models.  Future work may model atherosclerotic lesions, which not 
only represent areas of increased TF, but are often areas of stenosis and consequently 
locally increased wall shear rates.  Our initial modeling studies would suggest a 
protective effect; however, the decreased shear immediately downstream of the plaque 
may decrease the ability of unaffected vasculature to abrogate the thrombin load.   
Tissue factor surface presentation was assumed constant over the 60-min 
simulation period.  In other words, the TF stimulus responsible for initiating the reaction 
cascade is never 'turned off', and its catalytic activity is inhibited only by TFPI.  In 
addition to being challenging to define computationally, the dynamics of TF trafficking 
are complex and dependent on factor VIIa.  Upon binding, factor VIIa induces clathrin-
mediated cellular reuptake of the TF/VIIa complex in a time-dependent manner, with 
maximum internalization measured at 60 min [78].  Additionally, factor VIIa-dependent 
internalization of cell surface TF is promoted by TFPI [79].  While internalized TF is not 
recycled back to the cell surface, factor VIIa also causes the release of stored TF from 
the Golgi apparatus to the cell surface, resulting in a net increase of surface TF by 20-
30% [78].  It is unclear whether this mechanism is responsible for the dynamic increase 
in TF surface expression in endothelial cells and monocytes when exposed to 
inflammatory mediators including tissue necrosis factor (TNF-α), interleukin-1 (IL-1), 
histamine, endotoxin, oxidized lipoproteins, and heme [68, 80-83].  Recently, the 
phenomena of 'TF decryption' has been described in response to cellular activation [68, 
84].  Though the mechanism and kinetics of decryption have not been well-defined, it 
has been suggested that post-translational reduction of an allosteric disulfide bond 
between two extracellular immunoglobulin-like domains may be required for enhanced 
binding affinity for factor VIIa.  In a murine model of endothelial cell injury, TF-initiated 
fibrin formation was directly correlated to the activity of the oxidoreductase protein 
disulfide isomerase (PDI) released from adherent platelets and vascular wall cells at the 
 72 
injury site [85].  Finally, surface-bound TF may be physically inhibited by fibrin and 
platelet deposition [9].  The time-dependent profile of active tissue factor presentation on 
the cell surface is complex and warrants further consideration in our computational 
model.  Additionally, circulating TF, both soluble and lipid-bound, was excluded from the 
model as its role in thrombosis continues to be elucidated [86].  Alternatively spliced 
soluble tissue factor has been identified with retained procoagulant activity.  This isoform 
of TF is incorporated into growing thrombi when exposed to phospholipids and has been 
induced from endothelial cells by inflammatory mediators [87, 88].  Additionally, TF 
incorporated within the membrane of circulating microparticles shed from a variety of cell 
types has been studied in relation to coronary artery disease, inflammation, and 
cardiopulmonary bypass [89-92].  
Thrombomodulin expression was also assumed to remain constant over the 60-
min flow period.  Although a number of agents are known to affect TM expression, 
including cyclic adenosine monophosphate (cAMP), retinoic acid, and numerous 
inflammatory mediators, several of these factors affect expression on a transcriptional 
level [93-96], and thus do not affect our assumption of constant TM density over the 60-
min time period.  In contrast, internalization, degradation, and recycling of TM are 
temporally relevant events that may be mediated by thrombin [97].  Following a 5-min 
exposure to thrombin, radiolabeled cell surface TM on cultured endothelial cells 
decreased linearly to less than 50% of its original concentration within 30 min, 
accompanied by cessation of cofactor activity.  TM surface concentration returned to 
baseline by 90 min.  However, in the presence of physiologic concentrations of protein 
C, thrombin-mediated endocytosis was inhibited [98].  Additionally, homocysteine, a 
sulfur-containing amino acid formed during the metabolism of methionine, can 
irreversibly eliminate TM cofactor activity in cultured endothelial cells by reducing the 
disulfide-bond rich EGF-like domains [99].  However, concentrations of homocysteine 
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used in this study were 103-times higher than normal the normal physiologic range as 
well as levels observed in inherited hyperhomocysteinemia, and thus the relevance of 
TM inactivation by homocysteine remains unclear.  TM activity may also be inactivated 
by neutrophil-mediated oxidative damage to a susceptible methionine residue on the 
sixth EGF-like domain of TM [100].  While surface TM activity may be affected by a 
number of factors, the assumption of steady TM over the course of our simulation period 
is a reasonable one. 
Only a limited portion of the intrinsic pathway is included in the model.  Factor 
IXa is assumed to be generated solely by TF/ VIIa without participation of factors XI and 
XII (Hageman factor).  The role of the intrinsic, or contact pathway in the activation of 
coagulation in vivo remains undefined.  In vitro, factor XII is autoactivated to XIIa when 
exposed to negatively charged surfaces in a reaction involving high molecular weight 
kininogen (HMWK) and prekallikrein.  Factor XIIa, in turn, catalyzes the activation of 
factor XI, and factor XIa activates factor IX in the classic 'cascade' or 'waterfall' model of 
coagulation [101].  In vivo, however, the role of factor XII in coagulation is unclear, with 
reports of increased risk of thrombosis associated with both deficiency and elevation of 
factor XII [102-105].  Furthermore, it has been shown that thrombin is in fact 10-times 
more effective than factor XIIa in activating factor XI, and that factor XIIa-independent 
activation of XI may be further enhanced in the presence of glycosaminoglycans [101, 
106].  Alternate physiologic roles for factor XII, HMWK, and prekallikrein have been 
proposed in processes including vasodilation, inflammation, fibrinolysis, cell adhesion, 
and angiogenesis [107].  In contrast, factor XI deficiency, or hemophilia C, is associated 
with a mild to moderate bleeding diathesis, specifically in the settings of trauma and 
surgery [108], and high levels of factor XI are associated with increased risk of venous 
and arterial thrombosis [109-111].  In contrast, it has been suggested that factor XI may 
be important in sustaining coagulation once tissue factor has been blocked by either 
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TFPI or growing thrombus formation [42, 112].  Notably, even in the absence of factor 
XI, our model reflects the role of intrinsic tenase in amplifying thrombin generation after 
the initiation phase.  While the dominant mechanism for factor IX activation seems to be 
TF/VIIa mediated, the physiologic role of factor XIa continues to evolve and may be 
considered in future model iterations.   
Additional biochemical constituents related to coagulation that were not 
described by our model include, but are not limited to, protein C inhibitor (PCI), protein 
S, heparin cofactor II (HcII), von Willebrand factor (vWF), and endothelial protein C 
receptor (EPCR).  Protein C inhibitor, as well as 1-antiproteinase inhibitor and 2-
macroglobulin, inactivates activated protein C [113, 114].  Heparin cofactor II is a serine 
protease inhibitor homologous to ATIII that binds thrombin, but not factors IXa or Xa, in 
the presence of dermatan sulfate [115].  Von Willebrand factor protects factor VIIIa from 
APC-mediated inactivation [116].  EPCR is a transmembrane protein that promotes 
thrombin-TM catalyzed protein C activation by facilitating the association of protein C 
with the cell surface and promoting the assembly of the substrate-enzyme complex 
[117].  Although these pathways are relatively well characterized, the impact of these 
mediators on the overall system was believed to be outweighed by the computational 
effort required to define the additional species and kinetic parameters.  Protein S is a 
vitamin K-dependent plasma protein that acts as a necessary cofactor for the 
anticoagulant functions of activated protein C [118].  The cofactor activity of protein S 
was accounted for in the model through the choice of kinetic parameters for APC-
mediated inactivation of factor Va and VIIIa which were measured in the presence of 
physiologic concentrations of protein S [25].  However, heterozygous protein S 
deficiency is associated with thrombotic risk similar to that cased by heterozygous 
protein C deficiency, and APC resistance caused by acquired protein S deficiency is 
thought to be a contributory factor in hypercoagulability associated with pregnancy and 
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oral contraceptive use [119, 120].  Thus mechanistic inclusion of protein S may be useful 
for the representation and study of pathologic states.   
The computational model considered only free TFPI, not associated with 
circulating lipoproteins nor inducible from cellular sources, specifically endothelial cells 
and platelets [42].  Lipoprotein-bound TFPI does not retain its anticoagulant activity and 
is thought to play a role in atherosclerosis [121].  In culture, the majority of TFPI 
synthesized by endothelial cells remains sequestered within granules near the cell 
surface [122].  The rapid release of TFPI may be induced in a dose-dependent manner 
by heparin infusion [123, 124] and thrombin exposure in culture [125].  The rates of 
release in response to stimulation in vivo are not well-defined.   
Likewise, while the fibrinolytic pathway and platelet activation, adhesion, and 
aggregation are essential components of overall hemostasis, mathematical description 
of these pathways are beyond the scope of the current investigation.  Such undertakings 
require the consideration of rheological and mechanical phenomena as well as 
biochemical pathways.  Anand et al. have described some partial models of the 
formation and lysis of fibrin clots, including models of the extrinsic and fibrinolytic 
pathways in the absence of flow and continuum mechanical models of loose fibrin clots 
in a flow field [126, 127].  Others have developed methods to computationally describe 
the mechanical aspects of the motion, collision, adhesion, and cohesion of platelets 




With the advances in computational methods, theoretical models of coagulation 
may consider many phenomenological aspects efficiently and more completely. 
Compared to previous models of blood coagulation, we have presented the most 
 76 
comprehensive finite element model of coagulation reactions under flow to date with 
particular attention to spatial regulation.  In addition to the procoagulant reactions of the 
intrinsic, extrinsic, and common pathways, three physiologically relevant inhibitory 
pathways were mechanistically considered.  By eliminating the assumption of spatial 
homogeneity and describing discrete sites of TF and TM surface reactivity, localization 
of thrombin formation by downstream TM was not only demonstrated, but quantified by 
the definition of an effective prothrombotic zone in two dimensions.  While extension of 
thrombin generation away from the wall towards the center of the vascular space may 
contribute to vessel occlusion and stasis of flow, prothrombotic effects which extend 
downstream beyond the discrete site of injury to interact with subsequent lesions are 
critical given the systemic nature of atherosclerotic disease.  The TM-APC pathway is a 
key determinant of the overall thrombin response in the setting of multiple TF-laden 
lesions.   
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CHAPTER 4  
 
SIMULATED THROMBIN GENERATION PROFILES AS A PREDICTOR OF 
THROMBOTIC RISK AMONG PRE-MENOPAUSAL WOMEN 
Abstract 
A large number of individuals are at risk for deep venous thrombosis (DVT) due 
to alterations in multiple coagulation factors and inhibitors secondary to malignancy, 
drug interactions, or other general medical conditions.  We have utilized a computational 
model of blood coagulation, which addresses the interplay between biochemical factors, 
blood flow, and physiologic surface initiation of coagulation, to calculate an 
individualized, systems-based metric of clotting potential, FSTG, for 210 pre-
menopausal women in the Leiden Thrombophilia Study (LETS).  Both DVT and oral 
contraceptive (OC) use were associated with higher values of FSTG.  We demonstrated 
a 166% increased risk of DVT for each standard deviation increase in FSTGvenous above 
the mean that remained highly predictive after adjustment for age and OC status 
(adjusted OR 2.66; 95% CI 1.69-4.19; P<0.0001).   
 
4.1. Introduction 
As early as the 19th century, certain clinical settings have been associated with 
increased risk of thrombosis.  These acquired thrombophilias include both rare and 
common conditions such as cancer, hormone therapy, nephrotic syndrome, 
antiphospholipid syndrome, and hyperhomocysteinemia.  Over one hundred million 
women worldwide are prescribed exogenous hormones as oral contraceptives or for 
postmenopausal hormone replacement.  Oral contraceptive use is associated with a 2 to 
6-fold increased risk of venous thrombosis, 6-fold increased risk of cerebral vein 
thrombosis [1], 5-fold increased risk of myocardial infarction, and 3-fold increased risk of 
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ischemic stroke [2].  The risk is particular high during the first year of use and among 
women with underlying coagulation abnormalities or a history of venous thromboembolic 
event (VTE) [3].  Several population-based studies have reported elevations in plasma 
levels of factors II, VII, VIII, X, and fibrinogen, lower plasma levels of factor V, ATIII, 
protein S, and circulating thrombomodulin, and decreased activated partial 
thromboplastin time (aPTT) [4-7].  Additionally, acquired APC resistance comparable to 
that found in heterozygous factor V Leiden has been observed in women prescribed 
third-generation oral contraceptives [8, 9].  
Presently, thrombophilia screening is generally limited to inheritable conditions, 
such as protein C/S deficiencies, antithrombin III deficiency, factor V Leiden 
polymorphism (G1691A), or activated protein C resistance, prothrombin G20210A, or 
hyperprothrombinemia, and dysfibrinogenemia [10].  Additional assays include 
antiphosholipid antibody, lupus anticoagulant, and anticardiolipin antibody tests.   While 
these tests are available, prohibitive costs limit their utility for widespread population 
screening.  Thus, current guidelines by the College of American Pathologists (CAP) and 
the American College of Medical Genetics (ACMG) recommend that these tests be 
reserved for those patients who present with a venous thromboembolic event (VTE) and 
a high suspicion of hereditary thrombophilia, characterized by initial presentation <50 
years of age, recurrent thromboembolic events, unusual site of thrombosis, such as 
mesenteric vein and upper extremities, or a strong family history of thrombosis [11, 12].  
Additionally, testing is recommended for patients with pregnancy or OC-associated VTE.  
Screening is not currently performed on asymptomatic patients to assess the risk of 
having developed an acquired hypercoagulable state, even among high risk subgroups, 
such as those on oral contraceptives.   
Several population-based studies, including the Leiden Thrombophilia Study 
(LETS), have compiled considerable data regarding thrombotic risk associated with 
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increases in individual plasma coagulation factor levels.  Specifically, factors II, VIII, and 
IX had adjusted odds ratios calculated using a 90th percentile cutpoint of 2.1, 4.8, and 
2.5, respectively, for first-time deep venous thrombosis (DVT) [13-15].  However, there 
are conflicting studies regarding the association of elevations in these factors with risk of 
recurrent DVT [16-18].  Notably, increased levels of factors V, VII, and X were not 
independently associated with venous thrombosis [19-21].  It is generally accepted that 
changes in individual coagulation factors are not sufficiently predictive for assessing risk 
in a clinical setting due to the highly dynamic and complex nature of blood coagulation, 
which includes numerous positive and negative feedback mechanisms [22].  It is clear 
that a systems-based approach, which does not rely on any one intermediary of 
coagulation, but rather, considers initiation, amplification, and regulation of thrombin 
generation as an integrative network, is required to adequately assess hemostatic 
status.  In this study, we utilized a finite element model of surface-induced blood 
coagulation under flow to simulate thrombin generation based on patient coagulation 
factor profiles obtained from the Leiden Thrombophilia Study (LETS) and evaluated the 
association between simulated thrombin levels and risk of deep venous thrombosis 
among oral contraceptive users.   
 
4.2. Methods 
4.2.1. Study populations 
The Leiden Thrombophilia Study (LETS) [13-15] is a case-control study from the 
Netherlands with enrollment between 1988 and 1992 comparing participants with a first-
time, objectively diagnosed DVT to sex and age-matched controls (N=474 per study 
arm).  Original exclusion criteria included known malignancies and age greater than 70 
years.  Blood samples were drawn between 6 and 56 months from the date of 
thrombosis.  We analyzed pre-menopausal females whose OC status was known and 
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unchanged at the time of thrombosis and blood draw.  Additionally, participants on oral 
anticoagulants were excluded.  Our study groups were composed of 80 case individuals 
and 130 control individuals.  Coagulation factor levels were reported as percentages and 
were converted to molar concentrations by multiplying by published physiologic values 
(Table 4.1) [22-24].  
 
Table 4.1. Reference plasma concentrations 
   
Coagulation factor Plasma level (nM) Ref. 
Factor II 1400 [22] 
Factor V 20 [22] 
Factor VII 10 [22] 
Factor VIII 0.7 [22] 
Factor IX 90 [22] 
Factor X 170 [22] 
Antithrombin III 2400 [23] 
Protein C 60 [22] 
Protein S 300 [22] 





4.2.2. Numerical model of thrombin generation 
A finite element model has been formulated that describes thrombin generation 
under defined flow conditions, initiated and modulated by spatially discrete regions of 
surface-bound tissue factor and thrombomodulin, respectively (Figure 4.1).  The model 
incorporates fluid phase and surface-localized reactions of the extrinsic, intrinsic, and 
common pathways, as well as three major inhibitory pathways.  The spatially 
heterogeneous model describes coagulation events that occur following tissue factor 
exposure at a discrete site and incorporates mechanisms that regulate thrombin 
generation, including those mediated by an intact endothelium, represented as a 
thrombomodulin containing surface.  Specifically, we assume that the coagulation 
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cascade is initiated by binding of factor VIIa to tissue factor, leading to the formation of 
extrinsic tenase.  Activation of factor X leads to activation of factors V and VII.  The 
resultant surface-associated complex, Xa/Va, or prothrombinase, cleaves prothrombin to 
thrombin, which serves as a positive feedback loop by activating factors V and VIII.  
Generation of activated factor VIIIa, in association with IXa, affords intrinsic tenase, or 
IXa/VIIIa.  We assume that factor IXa is generated solely by TF/VIIa without participation 
of intrinsic pathway factors XI and XII.  Inhibitory reactions include the inactivation of 
factors IXa, Xa, and thrombin, by antithrombin III.  Additionally, inhibition of TF/VIIa by 
tissue factor pathway inhibitor (TFPI) is incorporated into the model as a two-step 
process, whereby TFPI binds factor Xa, followed by its reversible association with 
TF/VIIa.  The protein C pathway serves as an additional negative feedback loop.  
Binding of thrombin to thrombomodulin leads to formation of activated protein C, which 
inactivates factors Va and VIIIa.  Protein S directly modulates the kinetic efficiency of the 
latter inactivation reactions, but its interactions as a cofactor are not explicitly described.   
The reaction area of interest is modeled as a two-dimensional flow field with 
upper and lower inert and reactive surfaces, respectively.  Steady, one-dimensional, 
parabolic flow is assumed.  Convective-diffusive transport is described by the 
conservation equation.  All fluid-phase zymogen and enzyme concentrations are initially 
set to zero.  The surface density of tissue factor and thrombomodulin remain constant, 
and at the outset both are free of bound cofactors. Convective flux transports 16 fluid 
phase species into the flow field at constant inlet concentrations derived from mean 
physiologic values, unless otherwise specified.  Diffusion transports coagulation factors 
to the lower reactive surface, where reaction kinetics define flux boundary conditions.  
The reactive boundary is divided into localized upstream TF and downstream TM 
regions.  The primary analysis was performed assuming a 10 mm entrance region, 2 mm 
TF region, and a 34 mm TM region.  The length of the TF region is similar in dimension 
 89 
to that of a ruptured coronary plaque or vascular graft anastomosis [25].  Simulations 
were performed on a high performance computing (HPC) cluster (School of Chemical 
and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA).  All 
assumptions and implementation details along with basic validation of the model have 
been described elsewhere [26].   
An integrative parameter, flow simulated thrombin generation (FSTG), is derived 
from a consideration of the total thrombin generated beyond the site of TF expression at 
y=0 during the course of a 60-min flow period.  One-hour was chosen as the default 
simulation time to ensure that all phases of coagulation, e.g. initiation and propagation, 
were included in the analysis for all runs.  In other words, the simulation time exceeded 
the time course of the least thrombogenic simulation conditions.  FSTG represents the 
average thrombin concentration over the surface of interest during the course of the 
simulation and acts as a global variable incorporating both spatial and temporal 
information.  As described elsewhere, FSTG is a bimodal variable with values greater 
than 10 nM considered to exceed an activation threshold for a prothrombotic response.  
A value below 10 nM, notably the minimum thrombin concentration reported to induce 
platelet activation,[27] was categorized as lying either below an activation-threshold.  
In order to obtain the greatest sensitivity for evaluating the effects of 
perturbations in hemostatic concentration profiles, conditions of the vessel wall, which 
normally result in FSTG concentrations just below the activation threshold (FSTG < 
10nM) under venous (75 s-1) and arterial flow conditions (500 s-1) were utilized for all 
simulations.  These sub-threshold settings represent a „pivot point‟ between a dampened 
thrombin response and full activation of the coagulation cascade and have been 
previously determined and include a tissue factor bearing injury zone that is 2 mm in 
length in which the density of TF is 0.07 and 0.8 fmol/cm2 for venous and arterial 
conditions, respectively, and a downstream region presenting surface bound 
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thrombomodulin at a concentration of 1000 fmol/cm2.  While a different choice of 
parameters would result in quantitatively different thrombin responses, the comparative 
effects would be similar.   
 
4.2.3. Statistical analysis 
Female study participants whose OC status was known at the time of 
phlebotomy (N=210) were analyzed.  Descriptive statistics are reported as mean ± 
standard deviation for continuous variables and number (%) for categorical variables.  
Group-wise comparisons were performed using T-tests or nonparametric methods for 
continuous variables (based on data distributions) and Χ2 tests for categorical variables.     
FSTG was assessed as a continuous covariate in patients exceeding the 10 nM 
threshold for thrombin generation.  Associations between venous (FSTGvenous) and 
arterial (FSTGarterial) FSTG, coagulation factor levels, and DVT were evaluated using 
univariate and multivariable logistic regression.    Multivariable modeling was performed 
using stepwise selection with P≤0.10 required for model entry and P≤0.05 required for 
covariate retention in the final model.DVT models based on coagulation factors and/or 
FSTG as covariates were adjusted post-hoc for participant age and oral contraceptive 
use.  For continuous covariates, odds ratios (OR) are expressed per standard deviation 
change.  Significance was assessed at an α level of 0.05 and all statistical analyses 











Figure 4.1. Formulation of a spatially heterogeneous model of surface-induced 
thrombin generation in a flow field. Blood flow carries proteins into the flow field at 
constant inlet concentrations. Diffusion transports coagulation factors to the lower 
reactive surface, where reaction kinetics define flux boundary conditions. Convective flux 
removes soluble species at the outlet. The upper boundary is inert. Geometric conditions 
include a 10 mm inert entrance region (gray), 2 mm thrombin-initiating TF region (pink), 
and a 34 mm anti-thrombogenic TM region (blue). Flow simulated thrombin generation 
(FSTG) is defined as the integral of the downstream thrombin surface concentration over 






4.3.1. Descriptive statistics 
Among pre-menopausal female participants in LETS (N=210), approximately 
75% of the total population exceeded the 10 nM FSTG activation threshold (N=159 and 
N=152 for venous and arterial FSTG, respectively), with similar rates observed between 
control and DVT populations (Table 4.2).  OC use had no effect on threshold rates within 
the DVT group, but increased the proportion of participants that exceeded the activation 
threshold within the control group. 
 
 
Table 4.2a. Number of participants with FSTGvenous > 10 nM 
 
Group DVT 
No  Yes  
All participants 98/130 (75.3) 61/80 (76.3) 
Non-OC users 53/80 (66.3) 38/50 (76.0) 
OC users 45/50 (90.0) 23/30 (76.7) 
 




Table 4.2b. Number of participants with FSTGarterial > 10 nM 
 
Group DVT 
No  Yes  
All participants 93/130 (71.5) 59/80 (73.8) 
Non-OC users 49/80 (61.3) 35/50 (70.0) 
OC users 44/50 (88.0) 24/30 (80.0) 
 




Mean participant age was 38.2 ± 9.4 years.  Mean venous and arterial FSTG 
were 435.0 ± 221.2 and 656.3 ± 307.5 nM, respectively.  Descriptive statistics stratified 
by DVT status are shown in Table 4.3.  Higher concentrations of factors VII, VIII, IX, and 
X, and protein S were observed in the DVT population.  No difference was noted for the 
remaining plasma concentrations.  Stratified analysis based on DVT status revealed 
higher mean venous and arterial FSTG in the DVT group (FSTGvenous 535.8 nM versus 
372.3 nM, P<0.0001; FSTGarterial 789.8 nM versus 571.5 nM, P<0.0001) (Figure 4.2).  
Stratified analysis based on OC use revealed higher venous and arterial mean FSTG in 
OC users (FSTGvenous 514.5 nM versus 375.6 nM, P<0.0001; FSTGarterial 754.4 nM 
versus 576.8 nM, P=0.0003) (Figure 4.3).  Patients using OC were also younger (mean 
age 32.5 ± 10.1 versus 41.8 ± 6.9 years; P<0.0001).   
 
Table 4.3. Descriptive statistics for the entire study population* 
 
Variable DVT 
No  Yes  
Age (years) 38.3 ± 9.2 38.0 ± 9.7 
OCP use 50 (38.5) 30 (37.5) 
Factor II (%) 103.8 ± 15.2 109.2 ± 17.9 
Factor V (%) 119.6 ± 28.7 122.9 ± 32.2 
Factor VII (%) 110.0 ± 22.3 109.3 ± 17.9 
Factor VIII (%) 119.8 ± 31.4 135.4 ± 34.2 
Factor IX (%) 102.4 ± 22.6 113.6 ± 30.2 
Factor X (%) 104.8 ± 21.1 114.0 ± 23.0 
Antithrombin III (%) 98.6 ± 10.5 97.2 ± 12.0 
Protein C (%) 101.5 ± 16.5 107.1 ± 24.2 
Protein S (%) 91.8 ± 18.5 99.0 ± 19.6 
TFPI (ng/mL) 59.1 ± 13.9 59.7 ± 12.0 
Venous FSTG (nM) 372 ± 196 536 ± 224 
Arterial FSTG (nM) 572 ± 285 790 ± 296 
 
*Data are displayed as mean ± standard deviation for continuous variables and N 




4.3.2. Associations between FSTG and thrombosis 
DVT occurred in 80 participants (38.1%).  Univariate models of DVT are shown in 
Table 4.4.  Venous and arterial FSTG demonstrated highly significant univariate 
associations with DVT [OR 2.26, 95% CI (1.56-3.30) for FSTGvenous; OR 2.23, 95% CI 
(1.51-3.30) for FSTGarterial].  Adjusted ORs incorporating participant age and OC use 
were generally comparable to those observed with univariate analyses (Table 4.5).  
Multivariable associations with DVT were observed for FSTGvenous (OR 2.46; 95%CI 
(1.60-3.77); P<0.0001) and protein S (OR 1.48; 95% CI (1.03-2.14); P=0.0332) (Table 
4.6).  After adjusting the selected multivariable model for participant age and OC use, 
the association between DVT and FSTGvenous remained highly significant (OR 2.66; 95% 
CI 1.69-4.19; P<0.0001), but the adjusted OR for protein S was no longer significant 







Table 4.4. Univariate models with DVT as outcome 
  
Variable OR* (95% CI) P 
Venous FSTG 2.26 (1.56-3.30) <0.0001 
Arterial FSTG 2.23 (1.51-3.30) <0.0001 
Factor II 1.40 (1.05-1.87) 0.0227 
Factor V 1.12 (0.85-1.45) 0.4381 
Factor VII 1.39 (1.04-1.85) 0.0251 
Factor VIII 6.37 (2.07-19.62) 0.0013 
Factor IX 1.54 (1.15-2.05) 0.0032 
Factor X 1.53 (1.14-2.05) 0.0043 
ATIII 0.88 (0.66-1.16) 0.3597 
Protein C 1.33 (0.99-1.76) 0.0510 
Protein S 1.46 (1.10-1.95) 0.0097 
TFPI 1.05 (0.80-1.38) 0.7409 
 







Table 4.5. Single factor models adjusted for participant age and OC use 
 
Variable OR* (95% CI) P 
Venous FSTG 2.81 (1.81-4.36) <0.0001 
Arterial FSTG 2.56 (1.66-3.93) <0.0001 
Factor II 1.42 (1.06-1.90) 0.0187 
Factor V 1.14 (0.85-1.53) 0.3725 
Factor VII 1.46 (1.08-1.98) 0.0150 
Factor VIII 7.48 (2.33-24.40) 0.0007 
Factor IX 1.71 (1.24-2.34) 0.0009 
Factor X 1.70 (1.23-2.35) 0.0015 
ATIII 0.86 (0.64-1.15) 0.3054 
Protein C 1.38 (1.02-1.86) 0.0348 
Protein S 1.62 (1.17-2.24) 0.0040 
TFPI 1.05 (0.77-1.44) 0.7497 
 





Table 4.6. Multivariable models with DVT as outcome 
  
Variable Unadjusted Adjusted* 
OR(95% CI) P OR(95% CI) P 
Venous FSTG 2.46 (1.60-3.77) <0.0001 2.66 (1.69-4.19) <0.0001 
Protein S 1.48 (1.03-2.14) 0.0332 1.24 (0.80-1.91) 0.3318 
 








Figure 4.2. Venous and arterial FSTG distribution stratified by DVT status. Box 
plots represent median, 10th, 25th, 75th, and 90th percentiles. Open circles denote 5th and 
95th percentiles. Dashed lines indicate the mean. Asterisks indicate statistical 
significance. Flow simulated thrombin generation (FSTG) simulated over a 60-min flow 








Figure 4.3. Venous and arterial FSTG distribution stratified by OC use. Box plots 
represent median, 10th, 25th, 75th, and 90th percentiles. Open circles denote 5th and 95th 
percentiles. Dashed lines indicate the mean. Asterisks indicate statistical significance. 
Flow simulated thrombin generation (FSTG) simulated over a 60-min flow period at 




4.4.1. Patient screening and clinical assessment 
Given the large population at risk for thrombophilia, whether genetic or acquired 
and the complexities of integrating multiple risk factors, e.g. a FV Leiden carrier wishing 
to take oral contraceptives, there exists a need for a diagnostic screening tool to assess 
an individual's hemostatic state.  Due to low absolute risk, the cost-effectiveness of 
universal screening has been disparaged, particularly for those who have been 
prescribed oral contraceptives [28, 29].  However, selective thrombophilia screening and 
subsequent optimization of prophylactic treatment is likely to improve overall clinical 
outcomes [28, 30].  The primary methods of hemostatic assessment remains 
'prothrombin time' (PT) and 'activated partial thromboplastin time' (aPTT), both initially 
described over a half century ago.  Prothrombin time is a measure of the integrity of the 
extrinsic and common pathways and is defined as the time required for citrated plasma 
to clot following the addition of tissue factor and calcium.  Activated partial 
thromboplastin time, also measured using recalcified citrated plasma, is not dependent 
on tissue factor and therefore is a reflection of the integrity of the intrinsic pathway of 
coagulation.  APTT is particularly useful for identifying hemophilias and monitoring 
anticoagulant therapy [31].  Importantly, these assays are relatively insensitive to 
thrombotic risk.  A more global approach, the thrombin generation assay (TGA) uses a 
fluorogenic-based method to measure thrombin concentration over time in platelet-poor 
plasma, platelet-rich plasma, or whole blood.  In 1993, Hemker et al. [32] defined the 
term 'endogenous thrombin potential' (ETP) as the area under the curve of the thrombin 
generation curve, or 'thrombogram', and proposed the ETP as a sensitive marker of the 
capacity of plasma to form thrombin in response to a stimulus.  A number of studies 
have been performed to evaluate the predictive value of ETP with respect to hyper- and 
hypocoagulable states and hemostatic risk, recently reviewed by Van veen et al. [33].  
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However, there remains significant inter-laboratory variability, and standardization of 
techniques along with large prospective clinical trials are required before thrombin 
generation testing will be useful for routine clinical practice.   
Computational methods, in conjunction with individual coagulation protein 
profiles, have the potential to be high throughput screening tools given recent advances 
in both biochemical assays and computer processing.  Brummel-Ziedins et al. [34] input 
coagulation factor data from the control population of LETS into a 27-equation 
computational model [35] and examined the variation in simulated thrombin generation 
curves stratified by risk group, such as sex, increased body mass index (BMI > 26 
kg/m2), and use of oral contraceptives.  Input parameters included factors II, V, VII, VIII, 
IX, X, and the inhibitors ATIII and TFPI.  Output parameters included time to 10 nM of 
thrombin, time to maximum thrombin, maximum rate of thrombin generation (MaxR), 
maximum level of thrombin generation (MaxL), and total thrombin generated.  Together 
these parameters described the initiation, propagation, and termination phases of 
thrombin generation triggered by a fixed quantity of TF in solution.  Interestingly, their 
study identified subpopulations, termed 'fast- and slow-thrombin generators', which the 
authors proposed represented categories of risk.  OC use was associated with increases 
in thrombin-related parameters in both control and DVT populations.  The reported OR 
using the 90th percentile cutpoint for their greatest risk-associated parameter, MaxR, and 
OC use was 2.9 (95% CI 1.1-7.7).  Brummel-Ziedens et al. proposed the combination of 
an individual‟s plasma coagulation profile with a computational tool for evaluation of 
thrombotic risk, as well as assessment of global hemostatic changes following the 
initiation of oral contraceptives.  However, their numerical model was limited in its 
treatment of the protein C pathway and more critically, the absence of a well defined flow 
regime.   
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4.4.2. Assumptions and limitations 
Given the known association of OC use with thrombosis, we chose to focus on a 
cohort of pre-menopausal females with known and consistent OC status at the time of 
thrombosis and blood draw.  This subset of the original LETS case-control data set, 
matched by age and sex, may not be fully representative of the entire population.  
However, FSTGvenous remained highly associated with DVT when adjusted for 
demographic variables such as age and OC use, while other coagulation variables did 
not.  Prospective studies of FSTGvenous adjusting for other known risk factors of DVT 
including smoking, obesity, and race are warranted and are necessary to determine a 
clinically relevant cutpoint for FSTGvenous.   
Only those participants whose coagulation profiles yielded thrombin responses 
above an activation threshold (FSTG > 10) were included in the calculation of OR.  
Interestingly, similar rates of sub-threshold thrombin activation (~25%) were observed in 
control and DVT populations.  These individuals were predicted to have the lowest 
coagulable risk based on plasma factor levels alone.  While further refinements in the 
computational model, as previously noted, may improve its sensitivity to detect 
thrombotic risk, several mechanisms of thrombosis are not accounted for solely by 
measurable plasma factors of the coagulation cascade, including platelet activation, the 
fibrinolytic pathway, conditions that affect the surface expression of tissue factor or 
thrombomodulin, and local anatomic factors that predispose towards stasis.  Drawing 
from Virchow‟s triad, i.e. stasis, endothelial injury, and hypercoagulability, the presented 
model directly addresses the latter, but in contrast to other existing assays and models, 
our approach is also deeply rooted in the former two mechanisms through its 
incorporation of flow effects and surface TF and TM expression.   
It bears emphasis that the reaction pathways and related kinetic parameters are 
largely well-defined for the coagulation cascade, and furthermore, that no parameter 
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fitting was performed for our model system to calculate FSTG.  Kinetic parameters were 
obtained from the experimental literature of isolated reaction systems with preference 
given to studies deemed most relevant with respect to substrate and enzyme 
concentrations within the physiologic range, the presence of appropriate cofactors such 
as phospholipid surfaces and calcium, where applicable, and method of measurement.  
Given a different set of physiologically relevant parameters, the qualitative trends 
observed in our studies would have remained the same, and thus the model would still 
be useful for the comparison of altered hemostatic parameters.   
Furthermore, the simulations in this study assumed high levels of TM, previously 
shown to be within the transport-limited regime, and a fixed TF surface density which 
corresponded to thrombin generation just below the activation threshold for two flow 
conditions.  Near threshold conditions represent the most sensitive cases for detecting 
patients at risk of thrombosis and may be set precisely in terms of both spatial 
dimensions, density of surface-bound TF, and flow conditions.  Compared to well-mixed 
solution phase systems such as the thrombin generation assay, which operate well 
above the activation threshold, near threshold systems should be more sensitive in 
distinguishing between normal and susceptible population groups.  
While the inclusion of surface-bound TF and TM renders the computational 
model more sensitive and more physiologically relevant, diagnostically, there are no 
direct measures of alterations in TF or TM surface expression.  Circulating TF on the 
surface of monocytes and microparticles may be detected by flow cytometry, but their 
role in coagulation and the correlation to endothelial and subendothelial surface 
expression remain undefined at this time [36-39].  In contrast, soluble thrombomodulin 
has been established as a marker of early endothelial cell damage [40, 41].  Kunz et al. 
utilized monocyte expression of TM as an in vivo marker of endothelial cell expression in 
a familial study of TM deficiency.  However, the ability to quantify the extent of reduced 
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TM expression in endothelial cells was limited by the relatively low levels of TM found on 
the surface of circulating monocytes [42].  As measurement methods continue to evolve, 
TF and TM concentrations could easily be incorporated into our existing computational 
model.  
Protein S is a vitamin K-dependent plasma protein that acts as a necessary 
cofactor for the anticoagulant functions of activated protein C [43].  The cofactor activity 
of protein S was accounted for in the model through the choice of kinetic parameters for 
APC-mediated inactivation of factor Va and VIIIa, which were measured in the presence 
of thrombomodulin and physiologic concentrations of protein S [44].  Heterozygous 
protein S deficiency is associated with thrombotic risk similar to that caused by 
heterozygous protein C deficiency, and APC resistance caused by acquired protein S 
deficiency is thought to be a contributory factor in hypercoagulability associated with 
pregnancy and oral contraceptive use [8, 45].  Notably, in our subset population, protein 
S levels were actually greater in the DVT population than the control population.  Future 
mechanistic inclusion of protein S or the incorporation of laboratory APC sensitivity 
measurements may be useful for the representation and study of pathologic states.   
  
4.4.3. A systems-based method to predict thrombosis  
Our univariate analysis recapitulated some of the findings previously published 
by the LETS group [13-15] regarding the association of elevations in certain 
prothrombotic factors with venous thrombosis.  Adjusted for demographic variables, age 
and OC use, the systems-based variables, i.e. FSTGvenous and FSTGarterial, had the 
highest predictive value, followed by the individual factors VIII, IX, and X.  When all 
candidate covariates were allowed to compete and adjusted for age and OC use, only 
FSTGvenous remained significant.  Notably, FSTGvenous is a robust risk-associated variable 
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with little perturbation in the adjusted OR observed regardless of logistic model 
selection.   
We have utilized a computational model of blood coagulation, which addresses 
the interplay between biochemical factors, blood flow, and physiologic surface initiation 
of coagulation, to calculate a systems-based metric of clotting potential, FSTGvenous.  We 
demonstrated a 166% increased risk of DVT for each SD (221 nM) increase in 
FSTGvenous above the mean (435 nM) for our study population.  A large number of 
individuals are at risk for DVT due to alterations in multiple coagulation factors and 
inhibitors secondary to malignancy, drug interactions, or other general medical 
conditions.  While no one plasma marker is sufficiently predictive of thrombotic risk, a 
systems-based screening approach is both logical and necessary to identify the small 
subgroup of patients at risk that may benefit from oral anticoagulants to improve both 
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5.1. Summary of major findings 
In Section I, we developed and characterized a mathematical model of 
coagulation, which integrates the effects of reaction kinetics, a simple, yet 
computationally expandable, flow regime, and uniquely, heterogeneous surface 
expression of TF and TM.  The major findings of our studies include: (i) The FEM model 
simulated threshold effects with respect to the length of the TF site, TF and TM surface 
densities, and wall shear rate, and reproduced the classic time course characterized by 
initiation and amplification of thrombin generation.  Furthermore, even without parameter 
fitting, our TF length and density thresholds were consistent with several experimental 
reports.  (ii) Prothrombotic effects may extend significantly beyond the dimensions of the 
spatially discrete site of TF expression, a phenomenon that was quantified by the 
definition of an effective prothrombotic zone (EPZ).  Notably, the EPZ quantifies the vital 
function of hemostasis to confine thrombus formation to an injury site in both axial and 
radial directions.  (iii) In the setting of tandem TF-containing lesions, the relationship 
between the length of the EPZ and the interval distance between TF sites dictate the net 
response of the system.  Additive prothrombotic effects of sub-clinical lesions and 
interestingly, suppressive antithrombotic effects of intervening TM-containing regions 
were observed.   
In Section II, the computational model was applied to calculate an individualized, 
systems-based metric of clotting potential for 210 pre-menopausal women in the Leiden 
Thrombophilia Study (LETS).  Flow-simulated thrombin generation (FSTG) was 
reflective of three key qualities of the thrombin response: 1) intensity of response, 2) 
relative onset of amplification, and 3) localization of the thrombin foci near to the 
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upstream injury area, and was found to be a highly predictive parameter for deep venous 
thrombosis risk.  Diagnostic methods that utilize computational methods in conjunction 
with individualized biochemical profiles are both logical and necessary to identify the 
subgroup of patients at risk who may benefit from oral anticoagulants to improve cost-
effectiveness as well as patient safety and health. 
 
5.2. Future works 
5.2.1. Model development 
Next generations of model development should be aimed at addressing three 
areas: 1) addition of well-defined biochemical constituents previously omitted for 
computational simplicity, specifically factor XI and protein S, 2) exploration of complex 
flow fields and geometries, e.g., stenosis, pulsatile flow, and 3) modeling of transient TF 
surface presentation and additional surface-mediated pathways, e.g. heparin-like 
molecules.  
 The initial model described a steady, parabolic flow profile in a two-dimensional, 
rectangular flow field.  Several complex flow fields may be considered subsequently, 
given the versatility of the FEM approach.  In the context of atherosclerotic lesions, 
which represent sources of potential TF exposure and are often areas of stenosis, model 
geometry reflecting both single and tandem patterns of stenosis would be of immediate 
interest.  It may be hypothesized that increased shear rate in stenotic regions would 
provide a protective effect; however, the decreased shear immediately downstream of 
the plaque may decrease the ability of unaffected vasculature to abrogate the thrombin 
load.  Furthermore, the hemodynamic effects of tandem lesions and the measurement of 
fractional flow reserve (FFR) have generated recent interest [1, 2].  The interplay 
between these hemodynamic effects and the potential biochemical interactions reported 
in our studies, both additive and inhibitory, has direct clinical implications.  Finally, other 
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complex flow patterns such as arterial pulsatile flow, or modeling of venous flow patterns 
under sequential compression device (SCD) prophylaxis, may be considered.   
While our model includes regulation of thrombin formation by three physiologic 
biochemical pathways and blood flow, the model does not take into account physical 
inhibition of surface-bound TF by fibrin and platelet deposition.  Proposed modeling 
approaches include thrombin-independent and –dependent TF mechanisms.  For 
example, in a thrombin-independent system, TF surface concentration may be simply 
modeled by exponential or linear decay.  In thrombin-dependent models, fibrin and 
platelet deposition might be assumed to be proportional to thrombin generation, and thus 
available TF might decrease with increasing thrombin.   
 
5.2.2. Population-based studies 
Preliminary studies using a subset of data from LETS demonstrated that a 
systems-based parameter of coagulation was predictive of DVT risk and may have 
potential application as a diagnostic screening tool.  Future population-based studies 
may include: 1) a follow-up simulation study to examine the predictive value of FSTG for 
recurrent DVT using the LETS data, 2) FSTG analysis of the GATE (Genetic Attributes 
of Thrombosis Epidemiology, Centers for Disease Control, Atlanta, GA) study to 
examine the effects of age, race, smoking, obesity, and OC use, 3) prospective studies 
to better determine a clinical FSTG cutpoint, 4) prospective studies to examine the 
change in FSTG following initiation and/or discontinuation of oral contraceptives.   
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APPENDIX A:  
 
Model equations & boundary conditions 
The non-dimensionalized, convection-diffusion equation governs the transport of all 
soluble species:   
2 2
soln2 2 2
1i i i i
ts i ts
c c c cPe
D R
t x x y
 A.1 
 
Surface-associated reaction kinetics, which appear as flux boundary conditions for TF or TM-
defined boundaries, are listed for each individual species below.  Solution-phase reaction rates, 
Rsoln, are also defined.   
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Surface complexes are defined by their time derivatives.  7.1 
TF/ VIIa (extrinsic Xase) 
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APPENDIX B:  
 
Dimensional analysis 
 The governing equations of the mathematical model were non-dimensionalized for 
numerical convenience.  Listed below are the dimensional scales chosen.  Variables are as listed 
in the text.  Dimensionless variables are denoted with a superscript, *, while dimensional scales 
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Substituting, the governing equations become:  
* * 2 * 2 *
* *
soln* * 2 *2 *2
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APPENDIX C:  
 
Annotated MATLAB script for three spatially discrete TF regions 
 
% COMSOL Multiphysics Model M-file (THmodel6_spotted) 
% Generated by COMSOL 3.4 (COMSOL 3.4.0.248, $Date: 2007/10/10 16:07:51 
$) 




% COMSOL version 
clear vrsn 
vrsn.name = 'COMSOL 3.4'; 
vrsn.ext = ''; 
vrsn.major = 0; 
vrsn.build = 248; 
vrsn.rcs = '$Name:  $'; 
vrsn.date = '$Date: 2007/10/10 16:07:51 $'; 




% Define a rectangle of total length 4, height 1, anchored by the lower  




% Define intersection points to sub-divide lower reactive boundary 
% TF length 0.02, TF interval distance 1 
 

























% Name points (p) and boundaries (s) 
 













                
% Mesh 
 
% Increase mesh density over intersection points (vertices 3-8) and  
% over the lower surface (edges 2, 4-9) 
 
fem.mesh=meshinit(fem, ... 
                  'hauto',5, ... 
                  
'hmaxvtx',[3,0.01,4,0.02,5,0.01,6,0.02,7,0.01,8,0.02], ... 





fem.const = {'B','0.01/2', ...  % half-height 
  'L','3', ...     % length 
  'xs','L/L', ...     % longitudinal length scale 
  'ys','2*B/1', ...    % radial length scale 
  'alpha','xs/ys', ... 
  ... 
  'Df2','6.21e-7', ...     % diffusion coefficients 
  'Df2a','7.78e-7', ...     
  'Df5','3.74e-7', ...      
  'Df5a','4.69e-7', ...     
  'Df7','7.02e-7', ...     
  'Df7a','7.02e-7', ...     
  'Df8','4.67e-7', ...      
  'Df8a','4.7e-7', ...      
  'Df9','6.8e-7', ...      
  'Df9a','7.27e-7', ...     
  'Df10','6.64e-7', ...     
  'Df10a','7.22e-7', ...     
  'Dpc','6.53e-7', ...      
  'Dapc','6.75e-7', ...     
  'DLpc','(Dpc+Dapc)/2', ...  % averaged diffusivity for PC and APC 
  'DAT3','6.68e-7', ...     
  'Dtfpi','7.98e-7', ...    
  'Dtfpi10a','6e-7', ...     
 121 
  'Ds','1e-6', ...    % diffusion scale 
  ... 
  'Dqf2','Df2/Ds', ...     % normalized diffusion 
coefficients 
  'Dqf2a','Df2a/Ds', ... 
  'Dqf5','Df5/Ds', ... 
  'Dqf5a','Df5a/Ds', ... 
  'Dqf7','Df7/Ds', ... 
  'Dqf7a','Df7a/Ds', ... 
  'Dqf8','Df8/Ds', ... 
  'Dqf8a','Df8a/Ds', ... 
  'Dqf9','Df9/Ds', ... 
  'Dqf9a','Df9a/Ds', ... 
  'Dqf10','Df10/Ds', ... 
  'Dqf10a','Df10a/Ds', ... 
  'DqLpc','DLpc/Ds', ... 
  'DqAT3','DAT3/Ds', ... 
  'Dqtfpi','Dtfpi/Ds', ... 
  'Dqtfpi10a','Dtfpi10a/Ds', ... 
  ... 
  'c2in','1.4e-3', ...    % inlet concentrations 
  'c2ain','0', ... 
  'c5in','20e-6', ... 
  'c5ain','0', ... 
  'c7in','10e-6', ... 
  'c7ain','0.01*c7in', ...   % inlet VIIa is 1% of inlet 
VII 
  'c8in','0.7e-6', ... 
  'c8ain','0', ... 
  'c9in','90e-6', ... 
  'c9ain','0', ... 
  'c10in','160e-6', ... 
  'c10ain','0', ... 
  'cpcin','0.1e-3', ... 
  'capcin','0', ... 
  'ctfpiin','2.5e-6', ... 
  'cAT3in','1e-3', ... 
 
  'ts','60'};     % time scale 
 
% Application modes 
 
% Application mode 1 (factor X) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'c10'}; 
appl.name = 'f10'; 
appl.assignsuffix = '_f10'; 
 





bnd.c0 = {0,0,'c10in/cs',0,0}; 
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% Inward flux 
bnd.N = {0,'-kcat1q*ctf7as*c10/(Km10q+c10)-
kcat7q*c8a9as*c10/(Km7q+c10)', ... 
  0,0,'-kcat7q*c8a9as*c10/(Km7q+c10)'}; 
 
% Boundary type ('N0' is insulation; 'N' is flux, 'C' is concentration, 
'Nc' is  
% convective flux) 
 
bnd.type = {'N0','N','C','Nc','N'}; 
 
% c0, N, and type array indices.  bnd.ind[1] = 3, thus boundary 1  
% (inlet) is described by bnd.c0[3]='c10in/cs', bnd.N[3]=0, bnd.type  
% [3]='C', or in words, boundary 1 is defined by a Dirichlet boundary  
% condition with a constant concentration equal to c10in/cs.  Boundary  
% number labels are shown in  
Figure . 
 
bnd.ind = [3,1,1,2,5,2,5,2,5,4]; 
appl.bnd = bnd; 
 




% Anisotropic diffusivity tensor 
equ.dtype = 'aniso'; 
equ.dtensor = {{{'Dqf10/alpha^2';'Dqf10'}}}; 
 
% Flow velocity 
equ.u = 'Pey*un/alpha'; 
equ.v = 'Pey*0'; 
 
% Time-scaling coefficient 
equ.Dts = 'dts'; 
 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{1} = appl; 
 
% Application mode 2 (factor Xa) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'c10a'}; 
appl.name = 'f10a'; 
appl.assignsuffix = '_f10a'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
weakconstr.dim = {'lm2'}; 
prop.weakconstr = weakconstr; 




bnd.c0 = {0,0,'c10ain/cs',0,0}; 
bnd.N = {0,'kcat1q*ctf7as*c10/(Km1q+c10)+kcat7q*c8a9as*c10/(Km7q+c10)-
(ka2q*c5a*c10a-kd2q*c5a10as)', ... 
  0,0,'kcat7q*c8a9as*c10/(Km7q+c10)-(ka2q*c5a*c10a-kd2q*c5a10as)'}; 
bnd.type = {'N0','N','C','Nc','N'}; 
bnd.ind = [3,1,1,2,5,2,5,2,5,4]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqf10a/alpha^2';'Dqf10a'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
 
% Fluid-phase reaction rate 
equ.R = 'dts*(-ka9q*c10a*cAT3-(ka6q*ctfpi*c10a-kd6q*ctfpi10a))'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{2} = appl; 
 
% Application mode 3 (factor VIIa) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'c7a'}; 
appl.name = 'f7a'; 
appl.assignsuffix = '_f7a'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
weakconstr.dim = {'lm3'}; 
prop.weakconstr = weakconstr; 
appl.prop = prop; 
 
clear bnd 
bnd.c0 = {0,0,'c7ain/cs',0}; 
bnd.N = {0,'-ka1q*c7a*TFfreeq+kd1q*ctf7as',0,0}; 
bnd.type = {'N0','N','C','Nc'}; 
bnd.ind = [3,1,1,2,1,2,1,2,1,4]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqf7a/alpha^2';'Dqf7a'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.R = 'dts*(kcat9q*c10a*c7/(Km9q+c7)+kcat11q*c2a*c7/(Km11q+c7))'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{3} = appl; 
 
% Application mode 4 (TF/VIIa) 




appl.mode.class = 'FlPDEWBoundary'; 
appl.dim = {'ctf7as','ctf7as_t'}; 
appl.name = 'tf7a'; 
appl.assignsuffix = '_tf7a'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
weakconstr.dim = {'lm4','lm5'}; 
prop.weakconstr = weakconstr; 
appl.prop = prop; 
 




% Time-dependent weak term 
bnd.dweak = {0,'ctf7as_test*ctf7as_time'}; 
bnd.usage = {0,1}; 
 




% Weak term array indices. Boundary number labels shown in Figure.   
bnd.ind = [1,1,1,2,1,2,1,2,1,1]; 
appl.bnd = bnd; 
fem.appl{4} = appl; 
 
% Application mode 5 (prothrombin) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'c2'}; 
appl.name = 'f2'; 
appl.assignsuffix = '_f2'; 
 
clear bnd 
bnd.c0 = {0,0,'c2in/cs',0}; 
bnd.N = {0,'-kcat2q*c5a10as*c2/(Km2q+c2)',0,0}; 
bnd.type = {'N0','N','C','Nc'}; 
bnd.ind = [3,1,1,2,2,2,2,2,2,4]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqf2/alpha^2';'Dqf2'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{5} = appl; 
 
% Application mode 6 (thrombin) 




appl.mode.class = 'FlConvDiff'; 
appl.dim = {'c2a'}; 
appl.name = 'f2a'; 
appl.assignsuffix = '_f2a'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
weakconstr.dim = {'lm7'}; 
prop.weakconstr = weakconstr; 
appl.prop = prop; 
 
clear bnd 




bnd.type = {'N0','N','C','Nc','N'}; 
bnd.ind = [3,1,1,2,5,2,5,2,5,4]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqf2a/alpha^2';'Dqf2a'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.R = 'dts*(-ka5q*c2a*cAT3)'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{6} = appl; 
 
% Application mode 7 (factor Va) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'c5a'}; 
appl.name = 'f5a'; 
appl.assignsuffix = '_f5a'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
weakconstr.dim = {'lm8'}; 
prop.weakconstr = weakconstr; 
appl.prop = prop; 
 
clear bnd 
bnd.c0 = {0,0,'c5ain/cs',0}; 
bnd.N = {0,'-(ka2q*c5a*c10a-kd2q*c5a10as) -kcat4q*c5a*capc/(Km4q+c5a) 
+kcat10q*c10a*c5/(Km10q+c5)', ... 
  0,0}; 
bnd.type = {'N0','N','C','Nc'}; 
bnd.ind = [3,1,1,2,2,2,2,2,2,4]; 




equ.dtensor = {{{'Dqf5a/alpha^2';'Dqf5a'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.R = 'dts*(kcat8q*c2a*c5/(Km8q+c5))'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{7} = appl; 
 
% Application mode 8 (Va/Xa) 
% Weak form, boundary application mode 
 
clear appl 
appl.mode.class = 'FlPDEWBoundary'; 
appl.dim = {'c5a10as','c5a10as_t'}; 
appl.name = 'f5af10a'; 
appl.assignsuffix = '_f5af10a'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
weakconstr.dim = {'lm9','lmq10'}; 
prop.weakconstr = weakconstr; 
appl.prop = prop; 
 
clear bnd 
bnd.dweak = {0,'c5a10as_test*c5a10as_time'}; 
bnd.usage = {0,1}; 
bnd.weak = {0,'c5a10as_test*(ka2q*c5a*c10a-kd2q*c5a10as)'}; 
bnd.ind = [1,1,1,2,2,2,2,2,2,1]; 
appl.bnd = bnd; 
fem.appl{8} = appl; 
 
% Application mode 9 (protein C) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'cpc'}; 
appl.name = 'pc'; 
appl.assignsuffix = '_pc'; 
 
clear bnd 
bnd.c0 = {0,0,'cpcin/cs',0}; 
bnd.N = {0,'-kcat3q*cttms*cpc/(Km3q+cpc)',0,0}; 
bnd.type = {'N0','N','C','Nc'}; 
bnd.ind = [3,1,1,1,2,1,2,1,2,4]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'DqLpc/alpha^2';'DqLpc'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
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appl.equ = equ; 
fem.appl{9} = appl; 
 
% Application mode 10 (thrombin-TM) 
% Weak form, boundary application mode 
 
clear appl 
appl.mode.class = 'FlPDEWBoundary'; 
appl.dim = {'cttms','cttms_t'}; 
appl.name = 'ttm'; 
appl.assignsuffix = '_ttm'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
weakconstr.dim = {'lm12','lm13'}; 
prop.weakconstr = weakconstr; 
appl.prop = prop; 
 
clear bnd 
bnd.dweak = {0,'cttms_test*cttms_time'}; 
bnd.usage = {0,1}; 
bnd.weak = {0,'cttms_test*(ka3q*c2a*(TMq-cttms)-kd3q*cttms)'}; 
bnd.ind = [1,1,1,1,2,1,2,1,2,1]; 
appl.bnd = bnd; 
fem.appl{10} = appl; 
 
% Application mode 11 (factor IX) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'c9'}; 
appl.name = 'f9'; 
appl.assignsuffix = '_f9'; 
 
clear bnd 
bnd.c0 = {0,0,'c9in/cs',0}; 
bnd.N = {0,'-kcat5q*ctf7as*c9/(Km5q+c9)',0,0}; 
bnd.type = {'N0','N','C','Nc'}; 
bnd.ind = [3,1,1,2,1,2,1,2,1,4]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqf9/alpha^2';'Dqf9'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{11} = appl; 
 
% Application mode 12 (factor IXa) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
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appl.dim = {'c9a'}; 
appl.name = 'f9a'; 
appl.assignsuffix = '_f9a'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
weakconstr.dim = {'lm15'}; 
prop.weakconstr = weakconstr; 
appl.prop = prop; 
 
clear bnd 
bnd.c0 = {0,0,'c9ain/cs',0,0}; 
bnd.N = {0,'kcat5q*ctf7as*c9/(Km5q+c9)-(ka4q*c8a*c9a-kd4q*c8a9as)',... 
  0, 0,'-(ka4q*c8a*c9a-kd4q*c8a9as)'}; 
bnd.type = {'N0','N','C','Nc','N'}; 
bnd.ind = [3,1,1,2,5,2,5,2,5,4]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqf9a/alpha^2';'Dqf9a'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.R = 'dts*(-ka9q*c9a*cAT3)'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{12} = appl; 
 
% Application mode 13 (factor VIII) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'c8'}; 
appl.name = 'f8'; 
appl.assignsuffix = '_f8'; 
 
clear bnd 
bnd.c0 = {0,'c8in/cs',0}; 
bnd.type = {'N0','C','Nc'}; 
bnd.ind = [2,1,1,1,1,1,1,1,1,3]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqf8/alpha^2';'Dqf8'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.R = 'dts*(-kcat6q*c2a*c8/(Km6q+c8))'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{13} = appl; 
 
% Application mode 14 (factor VIIIa) 




appl.mode.class = 'FlConvDiff'; 
appl.dim = {'c8a'}; 
appl.name = 'f8a'; 
appl.assignsuffix = '_f8a'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
weakconstr.dim = {'lm17'}; 
prop.weakconstr = weakconstr; 
appl.prop = prop; 
 
clear bnd 
bnd.c0 = {0,'c8ain/cs',0,0}; 
bnd.N = {0,0,0,'-(ka4q*c8a*c9a-kd4q*c8a9as)-
kcat4q*c8a*capc/(Km4q+c8a)'}; 
bnd.type = {'N0','C','Nc','N'}; 
bnd.ind = [2,1,1,4,4,4,4,4,4,3]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqf8a/alpha^2';'Dqf8a'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.R = 'dts*(kcat6q*c2a*c8/(Km6q+c8))'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{14} = appl; 
 
% Application mode 15 (VIIIa/ IXa) 
% Weak form, boundary application mode 
 
clear appl 
appl.mode.class = 'FlPDEWBoundary'; 
appl.dim = {'c8a9as','c8a9as_t'}; 
appl.name = 'f8af9a'; 
appl.assignsuffix = '_f8af9a'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
weakconstr.dim = {'lm18','lmq19'}; 
prop.weakconstr = weakconstr; 
appl.prop = prop; 
 
clear bnd 
bnd.dweak = {0,'c8a9as_test*c8a9as_time'}; 
bnd.usage = {0,1}; 
bnd.weak = {0,'c8a9as_test*(ka4q*c8a*c9a-kd4q*c8a9as)'}; 
bnd.ind = [1,1,1,2,2,2,2,2,2,1]; 
appl.bnd = bnd; 
fem.appl{15} = appl; 
 
% Application mode 16 (factor V) 




appl.mode.class = 'FlConvDiff'; 
appl.dim = {'c5'}; 
appl.name = 'f5'; 
appl.assignsuffix = '_f5'; 
 
clear bnd 
bnd.c0 = {0,'c5in/cs',0,0}; 
bnd.N = {0,0,0,'-kcat10q*c10a*c5/(Km10q+c5)'}; 
bnd.type = {'N0','C','Nc','N'}; 
bnd.ind = [2,1,1,4,4,4,4,4,4,3]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqf5/alpha^2';'Dqf5'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.R = 'dts*(-kcat8q*c2a*c5/(Km8q+c5))'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{16} = appl; 
 
% Application mode 17 (factor VII) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'c7'}; 
appl.name = 'f7'; 
appl.assignsuffix = '_f7'; 
 
clear bnd 
bnd.c0 = {0,'c7in/cs',0}; 
bnd.type = {'N0','C','Nc'}; 
bnd.ind = [2,1,1,1,1,1,1,1,1,3]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqf7/alpha^2';'Dqf7'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.R = 'dts*(-kcat9q*c10a*c7/(Km9q+c7) -kcat11q*c2a*c7/(Km11q+c7))'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{17} = appl; 
 
% Application mode 18 (TFPI) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'ctfpi'}; 
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appl.name = 'tfpi'; 
appl.assignsuffix = '_tfpi'; 
 
clear bnd 
bnd.c0 = {0,'ctfpiin/cs',0}; 
bnd.type = {'N0','C','Nc'}; 
bnd.ind = [2,1,1,1,1,1,1,1,1,3]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqtfpi/alpha^2';'Dqtfpi'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.R = 'dts*(-(ka6q*ctfpi*c10a-kd6q*ctfpi10a))'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{18} = appl; 
 
% Application mode 19 (TFPI/ Xa) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'ctfpi10a'}; 
appl.name = 'tfpi10a'; 
appl.assignsuffix = '_tfpi10a'; 
 
clear bnd 
bnd.N = {0,0,0,'-(ka7q*ctfpi10a*ctf7as-kd7q*ctfis)'}; 
bnd.type = {'N0','C','Nc','N'}; 
bnd.ind = [2,1,1,4,1,4,1,4,1,3]; 
appl.bnd = bnd; 
 
clear equ 
equ.dtensor = {{{'Dqtfpi10a/alpha^2';'Dqtfpi10a'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.R = 'dts*(ka6q*ctfpi*c10a-kd6q*ctfpi10a)'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{19} = appl; 
 
% Application mode 20 (TFPI/ Xa/ TF/ VIIa) 
% Weak form, boundary application mode 
 
clear appl 
appl.mode.class = 'FlPDEWBoundary'; 
appl.dim = {'ctfis','ctfis_t'}; 
appl.name = 'tfi'; 
appl.assignsuffix = '_tfi'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
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weakconstr.dim = {'lm24','lmq25'}; 
prop.weakconstr = weakconstr; 
appl.prop = prop; 
 
clear bnd 
bnd.dweak = {0,'ctfis_test*ctfis_time'}; 
bnd.usage = {0,1}; 
bnd.weak = {0,'ctfis_test*((ka7q*ctfpi10a*ctf7as-kd7q*ctfis))'}; 
bnd.ind = [1,1,1,2,1,2,1,2,1,1]; 
appl.bnd = bnd; 
fem.appl{20} = appl; 
 
% Application mode 21 (antithrombin III) 
% Convection and diffusion application mode 
 
clear appl 
appl.mode.class = 'FlConvDiff'; 
appl.dim = {'cAT3'}; 
appl.name = 'AT3'; 
appl.assignsuffix = '_AT3'; 
clear prop 
clear weakconstr 
weakconstr.value = 'off'; 
weakconstr.dim = {'lm6'}; 
prop.weakconstr = weakconstr; 
appl.prop = prop; 
 
clear bnd 
bnd.c0 = {0,0,'cAT3in/cs'}; 
bnd.N = {0,0,0}; 
bnd.type = {'N0','Nc','C'}; 
bnd.ind = [3,1,1,1,1,1,1,1,1,2]; 
appl.bnd = bnd; 
 
clear equ 
equ.D = 'dts'; 
equ.dtensor = {{{'DqAT3/alpha^2';'DqAT3'}}}; 
equ.v = 'Pey*0'; 
equ.u = 'Pey*un/alpha'; 
equ.Dts = 'dts'; 
equ.R = 'dts*(-ka9q*c9a*cAT3-ka9q*c10a*cAT3-ka5q*c2a*cAT3)'; 
equ.dtype = 'aniso'; 
equ.ind = [1]; 
appl.equ = equ; 
fem.appl{21} = appl; 
 
fem.border = 1; 
fem.outform = 'general'; 
 
% Subdomain settings 
 
clear equ 
equ.ind = [1]; 
equ.dim = {'c10','c10a','c7a','c2','c2a','c5a','cpc','c9','c9a', ... 
  'c8','c8a','c5','c7','ctfpi','ctfpi10a','cAT3'}; 
 
% Subdomain expressions 
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equ.expr = {'f10a','1000000*c10a*cs', ... 
  'thrombin','1000000*c2a*cs', ... 
  'apc','1000000*capc*cs', ... 
  'f5a','1000000*c5a*cs', ... 
  'un','1-(-2*(0.5-y))^2', ... % normalized velocity profile, u(y) 
  'capc','cpcin/cs-cpc'};  % [APC]=[PC]in-[PC] 
fem.equ = equ; 
 
% Boundary settings 
 
clear bnd 
bnd.ind = [1,1,1,2,2,2,2,2,2,1]; 
bnd.dim = 
{'c10','c10a','c7a','ctf7as','c2','c2a','c5a','c5a10as','cpc', ... 
  'cttms','c9','c9a','c8','c8a','c8a9as','c5','c7','ctfpi','ctfpi10a', 
... 
  'ctfis','cAT3'}; 
 
% Boundary expressions 
 
bnd.expr = {'pro',{'','1000000000*c5a10as*es'}, ... % prothrombinase 
  'xxase',{'','1000000000*ctf7as*es'}, ...  % extrinsic Xase 
  'ixase',{'','1000000000*c8a9as*es'}, ...  % intrinsic Xase 
  'ttm',{'','1000000000*cttms*es'}, ...   % thrombin-TM 
  'TFfreeq',{'','TFq-ctf7as-ctfis'}, ... % free TF (dimensionless) 
  'freeTF',{'','1000000000*TFfreeq*es'}};   % free TF 
fem.bnd = bnd; 
 
% Scalar expressions 
 
fem.expr = {'gamma','500', ...% wall shear rate 
  'es','1e-9', ...   % surface concentration scale 
  'TFsurf','9*1e-9', ... % TF surface concentration 
  'TFq','TFsurf/es', ... 
  'TMsurf','100*1e-9', ... % TM surface concentration 
  'TMq','TMsurf/es', ... 
  ... 
  'kcat1','1.2', ...  % activation of X by TF/VIIa 
  'Km1','4.5*1e-4', ...  
  'kcat2','33', ...  % conversion of II by Va/Xa 
  'Km2','2.1*1e-4', ... 
  'kcat3','5.58', ...  % activation of PC by thrombin-TM 
  'Km3','0.7*1e-3', ... 
  'kcat4','0.4', ...  % inactivation of Va and VIIIa by APC 
  'Km4','2*1e-5', ... 
  'kcat5','0.34', ...  % activation of IX by TF/VIIa 
  'Km5','1.7e-4', ... 
  'kcat6','0.9', ...  % activation of VIII by thrombin 
  'Km6','2e-4', ... 
  'kcat7','20', ...  % activation of X by VIIIa/IXa 
  'Km7','1.6e-4', ... 
  'kcat8','0.23', ...  % activation of V by thrombin 
  'Km8','7.2e-5', ... 
  'kcat9','5.0', ...  % activation of VII by Xa 
  'Km9','1.2*1e-3', ... 
  'kcat10','0.046', ...  % activation of V by Xa 
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  'Km10','1.04e-5', ... 
  'kcat11','0.061', ...  % activation of VII by thrombin 
  'Km11','2.7e-3', ... 
  'Keq1','6e-4*1e-3', ... % TF/VIIa association/dissociation 
  'kd1','Keq1*ka1', ... 
  'ka1','1e5', ... 
  'Keq2','1e-7', ...  % Xa/Va association/dissociation 
  'kd2','Keq2*ka2', ... 
  'ka2','1e5', ... 
  'Keq3','1e-4*1e-3', ... % thrombin-TM association/dissociation 
  'kd3','Keq3*ka3', ... 
  'ka3','1e5', ... 
  'Keq4','1e-7', ...  % IXa/VIIIa association/dissociation 
  'kd4','Keq4*ka4', ... 
  'ka4','1e5', ... 
  'ka5','6.8', ...  % thrombin-ATIII inactivation 
  'ka9','2.6', ...  % IXa-ATIII inactivation 
  'kd6','3.3e-4', ...  % TFPI/Xa association/dissociation 
  'ka6','1.6e4', ... 
  'kd7','11e-4', ...  % TFPI/Xa-TF/VIIa assoc./dissoc. 
  'ka7','1e4', ... 
  ... 
  'cs','es/Ds/ts*ys', ... % concentration scale 
  'kcat1q','kcat1*ts', ... % dimensionless reaction parameters 
  'Km1q','Km1/cs', ... 
  'kcat2q','kcat2*ts', ... 
  'Km2q','Km2/cs', ... 
  'kcat3q','kcat3*ts', ... 
  'Km3q','Km3/cs', ... 
  'kcat4q','kcat4*ts', ... 
  'Km4q','Km4/cs', ... 
  'kcat5q','kcat5*ts', ... 
  'Km5q','Km5/cs', ... 
  'kcat6q','kcat6*ts', ... 
  'Km6q','Km6/cs', ... 
  'kcat7q','kcat7*ts', ... 
  'Km7q','Km7/cs', ... 
  'kcat8q','kcat8*ts', ... 
  'Km8q','Km8/cs', ... 
  'kcat9q','kcat9*ts', ... 
  'Km9q','Km9/cs', ... 
  'kcat10q','kcat10*ts', ... 
  'Km10q','Km10/cs', ... 
  'kcat11q','kcat11*ts', ... 
  'Km11q','Km11/cs', ... 
  'kd1q','kd1*ts', ... 
  'ka1q','ka1*cs*ts', ... 
  'kd2q','kd2*ts', ... 
  'ka2q','ka2*cs*ts', ... 
  'kd3q','kd3*ts', ... 
  'ka3q','ka3*cs*ts', ... 
  'kd4q','kd4*ts', ... 
  'ka4q','ka4*cs*ts', ... 
  'ka5q','ka5*cs*ts', ... 
  'ka9q','ka9*cs*ts', ... 
  'kd6q','kd6*ts', ... 
  'ka6q','ka6*cs*ts', ... 
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  'kd7q','kd7*ts', ... 
  'ka7q','ka7*cs*ts', ... 
  ... 
  'umax','B/2*gamma', ...   % maximum velocity 
  'Pey','umax*ys/Ds', ...   % modified Peclet term 
  'dts','ys^2/Ds/ts'};    % time-scaling coefficient 
 




% Integration coupling variables 
 
clear elem 
elem.elem = 'elcplscalar'; 
elem.g = {'1'}; 












  '(ntflux_c7a_f7a)*(cs*1e6)*alpha*Ds/(2/3*umax*2*B)'},{{},{},{}, ... 
  '(ntflux_c5a_f5a)*(cs*1e6)*alpha*Ds/(2/3*umax*2*B)'},{{},{},{}, ... 
  'cpcin/cs-
(ntflux_cpc_pc)*(cs*1e6)*alpha*Ds/(2/3*umax*2*B)'},{{},{},{}, ... 





























  {},'xy','xy',{}}}; 
bnd.ind = {{'1','2','3'},{'4','6','8'},{'5','7','9'},{'10'}}; 
src{1} = {{},bnd,{}}; 
elem.src = src; 
geomdim = cell(1,1); 
geomdim{1} = {}; 
elem.geomdim = geomdim; 
elem.var = 
{'f10a_out','th_out','f7a_out','f5a_out','apc_out','f9a_out', ... 
  'f8a_out','total_pro_tf','total_xxase_tf','total_ixase_tf', ... 
  'total_ttm_tm','total_pro_tm','total_xxase_tm','total_ixase_tm'}; 
elem.global = 
{'1','2','3','4','5','6','7','8','9','10','11','12','13','14'}; 
elem.maxvars = {}; 
elemcpl{1} = elem; 





% Extend mesh 
fem.xmesh=meshextend(fem, ... 
                     'linshape',[]); 
 
% Solve problem 
% Solver parameters: Output times 0 to 60, stepping by 0.05; Time 
dependent PARDISO linear system solver; Manual tuning of step size 
 
fem.sol=femtime(fem, ... 
                'u',0, ... 










                'tlist',[0:0.05:60], ... 
                'tout','tlist', ... 
                'tsteps','intermediate', ... 
                'initialstep',1e-7, ... 
                'maxstep',1e-4, ... 
                'linsolver','pardiso', ... 
                'itol',2.0E-6, ... 
                'errorchk','auto'); 
 





















Figure C.1. Boundary number labels.  (1) Inlet, (2) inert entrance region, (3) inert 
upper surface, (4,6,8) TF-expressing regions, (5,7,9) TM-expressing regions, (10) 
outlet.  The arrow indicates the direction of flow with velocity, u.  
